<SEC-DOCUMENT>0001193125-26-264029.txt : 20260609
<SEC-HEADER>0001193125-26-264029.hdr.sgml : 20260609
<ACCEPTANCE-DATETIME>20260609171527
ACCESSION NUMBER:		0001193125-26-264029
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20260609
DATE AS OF CHANGE:		20260609

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Shattuck Labs, Inc.
		CENTRAL INDEX KEY:			0001680367
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				812575858
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-292697
		FILM NUMBER:		261077125

	BUSINESS ADDRESS:	
		STREET 1:		500 W. 5TH STREET
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78701
		BUSINESS PHONE:		512-900-4690

	MAIL ADDRESS:	
		STREET 1:		500 W. 5TH STREET
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78701
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d122207d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 424(b)(5) <BR>Registration No. 333-292697 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P><DIV STYLE="position:relative; overflow:visible; width:651pt; height:30pt; transform-origin:bottom left; transform: rotate(-90deg) translate(-100%, 100%) translateX(30pt);">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and
the accompanying prospectus are not an offer to sell and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
</B></FONT></P></DIV><DIV STYLE="position:relative; overflow:visible; margin-left:48pt; margin-right:48pt; transform: translateY(-30pt);"> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>SUBJECT TO COMPLETION, DATED JUNE 9, 2026 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>PRELIMINARY PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>(To Prospectus Dated
January&nbsp;21, 2026) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANTS TO PURCHASE SHARES OF COMMON STOCK </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g122207g00p01.jpg" ALT="LOGO" STYLE="width:3.38958in;height:1.00625in;">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">We are offering &#8195;&#8195;&#8195;&#8195; of shares of our common stock and, in lieu of the shares of common stock to certain investors that so choose, <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase shares of our common stock. The purchase price of each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will equal the price per share at which shares of our common stock
are being sold to the public in this offering, minus $0.0001 per share of common stock, which is the exercise price of each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. The public offering price for each share of common stock is
$&#8195;&#8195;&#8195;&#8195;. We are also offering the shares of our common stock that are issuable from time to time upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. Our common stock trades on The Nasdaq Global
Select Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;STTK.&#8221; On June&nbsp;8, 2026, the last reported sale price for our common stock on Nasdaq was $3.90&nbsp;per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">There is no established public trading market for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, and we do not expect a market to develop. We
do not intend to apply for listing of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on Nasdaq or any securities exchange or nationally recognized trading system. Without an active trading market, the liquidity of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants will be limited. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#8220;<A HREF="#supptx122207_4">Risk
 Factors</A>&#8221; on page&nbsp;S-6 of this prospectus supplement, and under similar headings in the documents that are incorporated by reference into this prospectus supplement and the accompanying prospectus. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Per&nbsp;Pre-Funded</FONT></B><br><B>Warrant</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Underwriting discounts and commissions<SUP STYLE="font-size:75%; vertical-align:top">(1)
</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See the section titled &#8220;Underwriting&#8221; for a description of the compensation payable to the
underwriters. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state or foreign securities commission or regulatory authority has approved or disapproved of these
securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Delivery of the shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants is expected to be made on or about&#8195;&#8195;&#8195;,
2026. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">We have granted the underwriters an option for a period of 30 days to purchase up to an additional &#8195;&#8195;&#8195;shares of our common stock.
If the underwriters exercise the option in full, the total underwriting discounts and commissions payable by us will be $&#8195;&#8195;&#8195; and the total proceeds to us, before expenses, will be $&#8195;&#8195;&#8195;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><I>Joint Bookrunning Managers </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Leerink Partners</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>J.P. Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Piper Sandler</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Cantor</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus supplement, dated &#8195;&#8195;&#8195;&#8195;, 2026 </B></P></DIV> <p STYLE="clear:both; font-size:1pt; height:0">&nbsp;</p>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>Prospectus Supplement </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx122207_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-ii</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx122207_2">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx122207_3">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx122207_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx122207_5">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-10</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx122207_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-12</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx122207_7">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-13</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx122207_8">DESCRIPTION OF SECURITIES WE ARE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-15</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx122207_9">U.S. FEDERAL INCOME TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-17</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx122207_10">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-23</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx122207_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-30</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx122207_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-31</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx122207_13">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-32</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx122207_14">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-33</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_2">SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_3">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_6">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_7">SECURITIES WE MAY OFFER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_8">DESCRIPTION OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_9">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_10">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_11">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_12">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_13">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx122207_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document is part of the registration statement that we filed with the Securities and Exchange Commission, or the &#8220;SEC&#8221;, using a
&#8216;&#8216;shelf&#8217;&#8217; registration process, and consists of two parts. The first part is this prospectus supplement, including the documents incorporated by reference herein, which describes the specific terms of this offering. The
second part, the accompanying prospectus, including the documents incorporated by reference therein, gives more general information, some of which may not apply to this offering. This prospectus supplement relates to the offering of shares of our
common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. Before buying any of the securities that we are offering, we urge you to carefully read this prospectus supplement, together with the information incorporated by reference
as described under the headings &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference&#8221; in the accompanying prospectus, and any free writing prospectus that we have authorized for use in
connection with this offering. These documents contain important information that you should consider when making your investment decision. In general, when we refer only to the prospectus, we are referring to both the prospectus supplement and the
accompanying prospectus combined. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement describes the terms of securities offered in this offering and also adds to and updates
information contained in the documents incorporated by reference into this prospectus supplement. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the accompanying prospectus or
information contained in any document incorporated by reference into this prospectus supplement or accompanying prospectus that was filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) before the date of this prospectus supplement,
on the other hand, you should rely on the information in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document having a later date&#8212;for example, a document incorporated by
reference into this prospectus supplement&#8212;the statement in the document having the later date modifies or supersedes the earlier statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
not, and the underwriters have not, authorized any other person to provide you with information that is in addition to or different from that contained or incorporated by reference in this prospectus supplement or the accompanying prospectus, along
with the information contained in any permitted free writing prospectuses we have authorized for use in connection with this offering. Neither we nor the underwriters take any responsibility for, or can provide any assurance as to the reliability
of, any information other than the information contained or incorporated by reference in this prospectus supplement, the accompanying prospectus or any permitted free writing prospectuses we have authorized for use in connection with this offering.
You should assume that the information appearing in this prospectus supplement is accurate only as of the date on the front cover of this prospectus supplement. Our business, financial condition, results of operations and prospects may have changed
since that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information contained on, or accessible through, our website is not part of this prospectus supplement. We and the underwriters are
offering to sell, and seeking offers to buy, the securities offered hereby only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of the securities
in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement must inform themselves about, and observe any restrictions relating to, the offering of the securities
offered hereby and the distribution of this prospectus supplement outside the United States. This prospectus supplement does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any
securities offered by this prospectus supplement by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the context otherwise requires, we use the terms &#8220;Shattuck Labs,&#8221; &#8220;Shattuck,&#8221; &#8220;company,&#8221; &#8220;we,&#8221;
&#8220;us,&#8221; and &#8220;our&#8221; in this prospectus to refer to Shattuck Labs, Inc. and, where appropriate, our subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx122207_2"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following summary of our business highlights certain of the information contained elsewhere in, or incorporated by reference into, this prospectus
supplement and the accompanying prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our securities. You should carefully read this entire prospectus
supplement and the accompanying prospectus, including any information incorporated by reference, which are described under the headings &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by
Reference&#8221; herein and therein. In particular, you should carefully consider the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; in this prospectus supplement and in the accompanying prospectus, as well as those
contained in the other documents incorporated by reference herein. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. We are developing a
potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antibody for the treatment of inflammatory bowel disease and other inflammatory and immune-mediated diseases. Our expertise in protein
engineering and the development of novel tumor necrosis factor receptor therapeutics come together in our lead program, <FONT STYLE="white-space:nowrap">SL-325,</FONT> which we believe could be a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> death receptor 3 antagonist antibody. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Data from Phase 1 Clinical Trial of <FONT STYLE="white-space:nowrap">SL-325</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;8, 2026, the Company announced data from its Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">SL-325,</FONT> Shattuck&#8217;s lead DR3
blocking antibody candidate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Key Phase 1 Findings </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 1 trial is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human,</FONT></FONT> randomized, placebo-controlled trial
evaluating the safety, tolerability, pharmacokinetics (&#8220;PK&#8221;), receptor occupancy (&#8220;RO&#8221;), pharmacodynamics (&#8220;PD&#8221;), and immunogenicity of <FONT STYLE="white-space:nowrap">SL-325</FONT> in healthy volunteers. The
study enrolled 72 participants, across six single-ascending dose cohorts, with doses ranging from 0.1 mg/kg to 30.0 mg/kg, and three multiple-ascending dose cohorts, with doses ranging from 1 mg/kg to 10 mg/kg. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Immunogenicity: </B>Antidrug antibodies (&#8220;ADA&#8221;) to <FONT STYLE="white-space:nowrap">SL-325</FONT>
were detected in 3.7% [2/54] of participants who received <FONT STYLE="white-space:nowrap">SL-325.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In these two participants, ADA were low titer (&#8804;16), and no impact to PK or receptor occupancy was
observed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ADA assay used to detect ADA to <FONT STYLE="white-space:nowrap">SL-325</FONT> has a sensitivity of 5.0 ng/ml
and drug tolerance of up to <FONT STYLE="white-space:nowrap">SL-325</FONT> concentrations of 160.0 &micro;g/ml in the serum. For each participant in this Phase 1 trial, samples were analyzed over a time course, ensuring that samples from each
participant fell within the dynamic range of the assay across the full dose range, and thus limiting the possibility of false negative results. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Published and emerging data suggest that ADA to anti-TL1A antibodies impact efficacy. <FONT
STYLE="white-space:nowrap">SL-325&#8217;s</FONT> potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-mechanism</FONT></FONT> immunogenicity profile is expected to lead to improved efficacy at both the induction and
maintenance timepoints compared to anti-TL1A antibodies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Pharmacokinetics and Receptor Occupancy: </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Complete DR3 occupancy, as measured by blockade of TL1A binding, was observed at doses of 0.1 mg/kg and higher in
all participants. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Complete inhibition of TL1A binding was durable for more than 10 weeks, and extended PK modeling suggests that
complete inhibition of TL1A binding may be sustained for greater than 3 months at doses of greater than1 mg/kg of <FONT STYLE="white-space:nowrap">SL-325.</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The PK profile of <FONT STYLE="white-space:nowrap">SL-325</FONT> demonstrated proportional increases in Cmax and
AUClast across all dose levels. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Repeated dosing demonstrated an accumulation ratio of <FONT STYLE="white-space:nowrap">1.64-1.75.</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A subcutaneous formulation of <FONT STYLE="white-space:nowrap">SL-325</FONT> has been developed. These Phase 1
results indicate the potential for quarterly dosing at a volume compatible with an autoinjector pen. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Pharmacodynamics: </B>Clinical<B> </B>data now corroborate our previous preclinical findings that <FONT
STYLE="white-space:nowrap">SL-325</FONT> is a pure DR3 blocking antibody. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No evidence of DR3 agonism was observed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No evidence of <FONT STYLE="white-space:nowrap">SL-325</FONT> mediated lymphocyte proliferation or changes in
serum cytokines was observed in any participant at any dose level. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No increases in serum levels of TL1A from baseline were observed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Safety: </B><FONT STYLE="white-space:nowrap">SL-325</FONT> was well tolerated at all dose levels and upon
repeat dosing, with a favorable safety profile consistent with the TL1A inhibitor class. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There were no serious treatment-emergent adverse events (&#8220;TEAEs&#8221;) or serious adverse events.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">All treatment-related adverse events (&#8220;TRAEs&#8221;) were Grade 1. TRAEs were observed in 12 participants.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">RECEPTIVE-CD1</FONT> Phase 2b Trial of <FONT STYLE="white-space:nowrap">SL-325</FONT> in
Crohn&#8217;s Disease </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">RECEPTIVE-CD1</FONT> clinical trial is designed as a randomized, double-blind,
placebo-controlled Phase 2b clinical trial to evaluate the safety and efficacy of two dose levels of <FONT STYLE="white-space:nowrap">SL-325</FONT> as monotherapy versus placebo in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> Crohn&#8217;s disease. <FONT STYLE="white-space:nowrap">SL-325</FONT> will be administered intravenously, and the trial will include a <FONT
STYLE="white-space:nowrap">12-week</FONT> induction period, followed by a <FONT STYLE="white-space:nowrap">40-week</FONT> maintenance period, for a total of 52 weeks of treatment for each patient enrolled. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">RECEPTIVE-CD1</FONT> is expected to enroll approximately 174 patients,
randomized 1:1:1, with patients receiving either low dose <FONT STYLE="white-space:nowrap">SL-325,</FONT> high dose <FONT STYLE="white-space:nowrap">SL-325,</FONT> or placebo. <FONT STYLE="white-space:nowrap">RECEPTIVE-CD1</FONT> will enroll
patients at clinical sites in the United States, Canada, and Europe. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">RECEPTIVE-CD1</FONT> is expected to enroll patients with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> Crohn&#8217;s disease, as defined with a Crohn&#8217;s Disease Activity Index (&#8220;CDAI&#8221;) score of between 220 and 450. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The primary endpoint is expected to be endoscopic response at Week 12, and the key secondary endpoint will be
clinical remission at Week 12. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients randomized to the placebo arm will be eligible to receive <FONT STYLE="white-space:nowrap">SL-325</FONT>
after the <FONT STYLE="white-space:nowrap">12-week</FONT> induction period </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The primary endpoint, endoscopic response at 12 weeks, is expected to be disclosed in the first half of 2028
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SL-846:</FONT> A Dual DR3 and <FONT STYLE="white-space:nowrap">IL-23</FONT> Receptor Blocking
Antibody </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SL-846</FONT> is our lead bispecific product candidate and is designed to simultaneously bind to DR3 and
to <FONT STYLE="white-space:nowrap">IL-23</FONT> receptor, blocking the interaction with TL1A and <FONT STYLE="white-space:nowrap">IL-23,</FONT> respectively, while avoiding the risk of immune complex formation and resulting ADA challenges of the
TL1A-based bispecifics. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">SL-846</FONT> is an <FONT STYLE="white-space:nowrap">Fc-silenced,</FONT>
half-life extended, IgG1 bispecific antibody </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Preclinical data demonstrated that <FONT STYLE="white-space:nowrap">SL-846</FONT> was equipotent, or more potent,
than sequence equivalents of risankizumab and icotrokinra controls in multiple <I>in vitro </I>and cell-based potency assays </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">SL-846</FONT> is currently being evaluated in an ongoing <FONT
STYLE="white-space:nowrap">IND-enabling</FONT> GLP toxicology study in <FONT STYLE="white-space:nowrap">non-human</FONT> primates. Safety and immunogenicity data are expected in the second half of 2026. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Shattuck expects to submit an IND for <FONT STYLE="white-space:nowrap">SL-846</FONT> in the first half of 2027.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Warrant Exercises </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
June&nbsp;9, 2026, we announced that we have received notices to exercise totaling approximately 50.6&nbsp;million common stock warrants to date, representing approximately 96% of the warrants issued in the Company&#8217;s August&nbsp;4, 2025
private placement. The exercise of these warrants is expected to result in aggregate gross proceeds of approximately $54.9&nbsp;million. As of March&nbsp;31, 2026, we had received aggregate gross proceeds of approximately $5.6&nbsp;million pursuant
to the exercise of 5,147,773 warrants. We expect to receive additional aggregate gross proceeds totaling approximately $49.3&nbsp;million from the exercise of 45,438,709 common stock warrants since March&nbsp;31, 2026. Together with existing cash
and cash equivalents and short term investments of approximately $90.4&nbsp;million as of March&nbsp;31, 2026, we expect to be able to fund operations into 2029. This cash runway guidance is based on our current operational plans and excludes any
additional capital that may be received (other than from the exercise of these common stock warrants), proceeds from business development transactions, and/or additional costs associated with clinical development activities that may be undertaken.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated in 2016
in the State of Delaware. Our principal executive offices are located at 500 W. 5th Street, Suite 1200, Austin, TX 78701 and our telephone number is (512) <FONT STYLE="white-space:nowrap">900-4690.</FONT> Our website is www.shattucklabs.com. The
information on, or that can be accessed through, our website is not part of this prospectus and is not incorporated by reference herein. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications
of being a Smaller Reporting Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation <FONT
STYLE="white-space:nowrap">S-K.</FONT> Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements and reduced disclosure
obligations regarding executive compensation. We will be a smaller reporting company and may continue to take advantage of the scaled-back disclosures available to smaller reporting companies for so long as (i)&nbsp;the market value of our common
stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our most recently completed second fiscal quarter or (ii)&nbsp;at the time of determination at the end of the
fiscal year, (a)&nbsp;our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year for which audited financial statements are then-available and (b)&nbsp;the market value of our common stock held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our most recently completed second fiscal quarter. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx122207_3"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD>&#8195;&#8195;&#8195;&#8195;&#8195; of shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pre-funded</FONT> warrants offered by us </P></TD>
<TD>We are also offering, in lieu of common stock to certain investors that so choose, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase &#8195;&#8195;&#8195;shares of our common stock. The purchase price of each <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant equals the price per share at which the shares of our common stock are being sold to the public in this offering, minus $0.0001 per share of common stock, which is the exercise price of each <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant. Each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will be exercisable at any time after the date of issuance of such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant,
subject to an ownership limitation. See the section titled &#8220;Description of Securities We Are Offering&#8221; for additional information. This prospectus supplement also relates to the offering of the shares of our common stock issuable upon
exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares of common stock </P></TD>
<TD>We have granted the underwriters an option, exercisable for 30 days from the date of this prospectus supplement, to purchase up to an additional &#8195;&#8195;&#8195;shares of our common stock at the public offering price, less underwriting
discounts and commissions on the same terms as set forth in this prospectus. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Total common stock to be outstanding immediately after this offering </P></TD>
<TD>&#8195;&#8195;&#8195;shares (of which &#8195;&#8195;&#8195;shares will be common stock), or&#8195;&#8195;&#8195;shares (of which &#8195;&#8195;&#8195;shares will be common stock) if the underwriters exercise their option to purchase additional
shares of our common stock in full, assuming no exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants offered and sold in this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that our net proceeds from this offering will be approximately $&#8195;&#8195;&#8195;million (or approximately $&#8195;&#8195;&#8195;million if the underwriters exercise in full their option to purchase additional shares of our
common stock), based on the public offering price of $ &#8195;&#8195;&#8195;per share, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to use the net proceeds from this offering to advance our ongoing and planned clinical trials and to develop and advance additional product candidates, as well as for working capital and general corporate
purposes. See &#8220;Use of Proceeds&#8221; on page S-12 of this prospectus supplement. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>Investing in our common stock involves a high degree of risk. See the information contained in or incorporated by reference under the heading &#8220;Risk Factors&#8221; on page <FONT STYLE="white-space:nowrap">S-6</FONT> of this prospectus
supplement, in the accompanying prospectus and in the documents incorporated by reference into this prospectus supplement and any free writing prospectus that we authorize for use in connection with this offering. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">The Nasdaq Global Select Market </P></TD>
<TD>&#8220;STTK.&#8221; There is no established public trading market for the pre-funded warrants, and we do not intend to apply for listing of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on Nasdaq or any securities exchange or
nationally recognized trading system. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of common stock that will be outstanding after this offering is based on
75,581,787 shares of common stock outstanding as of March&nbsp;31, 2026 and excludes, in each case, as of March&nbsp;31, 2026: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">47,487,573 shares of common stock issuable upon the exercise of common warrants to purchase common stock
outstanding as of March&nbsp;31, 2026 at a weighted-average exercise price of $1.0846; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">38,448,034 shares of common stock issuable upon the exercise of
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase common stock outstanding as of March&nbsp;31, 2026 at a weighted-average exercise price of $0.0001; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13,064,499 shares of common stock issuable upon the exercise of outstanding stock options under our 2020 Equity
Incentive Plan (&#8220;EIP&#8221;), with a weighted-average exercise price of $5.05 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">589,803 shares of common stock issuable upon the vesting of outstanding restricted stock units;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,559,581 shares of common stock reserved for future equity award grants under the EIP; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,660,870 shares of common stock reserved for future issuance under our 2020 Employee Stock Purchase Plan
(&#8220;ESPP&#8221;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares of our common stock that may be sold from time to time under our &#8220;at the market&#8221; equity
offering program with Leerink Partners LLC. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, all information in this prospectus
supplement assumes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of outstanding options and no vesting of restricted stock units or restricted common stock awards
after March&nbsp;31, 2026; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of common warrants to purchase common stock outstanding after March&nbsp;31, 2026 and no exercise of
pre-funded warrants to purchase common stock outstanding after March&nbsp;31, 2026; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants offered and sold in this offering;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the underwriters&#8217; option to purchase additional shares of our common stock.
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx122207_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our securities involves risks. You should carefully consider the risks, uncertainties and other factors described in our most recent Annual
Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as supplemented and updated by subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT>
that we have filed or will file with the SEC, and in other documents which are incorporated by reference into this prospectus supplement, including the risk factors and other information contained in or incorporated by reference into this prospectus
supplement before investing in any of our securities. Our business, financial condition, results of operations, cash flows or prospects could be materially adversely affected by any of these risks. The risks and uncertainties described in the
documents incorporated by reference herein are not the only risks and uncertainties that you may face. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to This Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The offering price was set by the board of directors and does not necessarily indicate the actual or market value of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors approved the offering price and other terms of this offering after considering, among other things: the number of shares authorized in
our certificate of incorporation; the current market price of our common stock; trading prices of our common stock over time; the volatility of our common stock; our current financial condition and the prospects for our future cash flows; the
availability of and likely cost of capital of other potential sources of capital; and market and economic conditions at the time of the offering. The offering price is not intended to bear any relationship to the book value of our assets or our past
operations, cash flows, losses, financial condition, net worth or any other established criteria used to value securities. The offering price may not be indicative of the fair value of the common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The price of our stock may be volatile, and you could lose all or part of your investment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading price of our common stock has fluctuated, and is likely to continue to fluctuate substantially in response to various factors, some of which are
beyond our control, including the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein. The realization of any of
these factors could have a dramatic and adverse impact on the market price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the stock market in general, and the market
for biotechnology and biopharmaceutical companies in particular, have historically been particularly volatile and experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of
these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. If the market price of our common stock does not exceed the price at which you purchase
your shares, you may not realize any return on your investment in us and may lose some or all of your investment. In the past, securities class action litigation has often been instituted against companies, including against us, following periods of
volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would materially adversely affect our
business, financial condition and results of operation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase shares of our common stock in this offering, or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants in lieu thereof, you will incur immediate and substantial dilution and may experience additional dilution in the future. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will suffer immediate and substantial dilution with respect to the common stock or the shares of common stock underlying the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants you purchase in this offering. The offering price will be substantially higher than the as adjusted net tangible book value per share of our common stock after this offering. If you
purchase common stock (or pre-funded warrants in lieu thereof) in this offering at the public offering price of $&#8195;&#8195;&#8195; per share (or $&#8195;&#8195;&#8195; per <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant in lieu
thereof), and assuming that the underwriters do not exercise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
their option to purchase additional shares of common stock in this offering, you will incur immediate and substantial dilution of $ &#8195;&#8195;&#8195;per share, representing the difference
between the public offering price of $&#8195;&#8195;per share and our pro forma net tangible book value per share as of March&nbsp;31, 2026. This dilution would be due to the substantially lower price paid by some of our investors who purchased
shares prior to this offering as compared to the price offered to the public in this offering and the exercise of stock options granted to our employees, directors and consultants. In addition, we have a significant number of stock options and <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants outstanding. To the extent outstanding stock options and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are exercised, new stock options are issued, the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants issued in this offering are exercised, restricted stock units vest and settle, or we issue additional shares of common stock in the future, including through the sale of equity or convertible
debt securities, there will be further dilution to new investors. The exercise of any of these outstanding options or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants would result in further dilution. As a result of the dilution to
investors purchasing shares in this offering, investors may receive significantly less than the purchase price paid in this offering, if anything, in the event of our liquidation. Further, because we expect we will need to raise additional capital
to fund our future activities, we may in the future sell substantial amounts of common stock or securities convertible into or exchangeable for common stock. Future issuances of common stock or common stock-related securities, together with the
exercise of outstanding stock options or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, if any, may result in further dilution. For a further description of the dilution that you will experience immediately after this offering, see the
section titled &#8220;Dilution.&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There is no public market for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants being offered
in this offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no established public trading market for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants being offered
in this offering, and we do not expect a market to develop. In addition, we do not intend to apply to list these <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on any securities exchange or nationally recognized trading system,
including Nasdaq. Without an active market, the liquidity of these <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be limited. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Holders of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants purchased in this offering will have no rights as common stockholders until such
holders exercise their <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and acquire our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until holders of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants acquire shares of our common stock upon exercise of such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, the holders will have no rights with respect to the shares of our common
stock underlying such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, such as voting rights or the rights to receive dividends. Upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, the holders will be
entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will not receive
significant additional funds upon the exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants being offered. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In certain
circumstances, each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant may be exercised by way of a cashless exercise, meaning that the holder may not pay a cash purchase price upon exercise, but instead would receive upon such exercise the
net number of shares of our common stock determined according to the formula set forth in the pre-funded warrant. Accordingly, we may not receive any additional funds upon the cashless exercise of the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants or if the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants altogether are not exercised at all. In addition, the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants have
an exercise price of $0.0001 per share of common stock, and as a result we will not receive significant additional funds upon their exercise even if not a cashless exercise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Significant holders or beneficial owners of our common stock may not be permitted to exercise <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants that they hold. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will not be entitled to exercise any portion
of any <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant which, upon giving effect to such exercise, would cause the aggregate number of shares of our common stock beneficially owned by the holder (together with its affiliates) to exceed a
specified percentage of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ownership is determined in accordance with the terms of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. As a result, you may not be able to exercise your <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants for shares of our common stock at a time when it would be financially beneficial for you to do so. In such circumstance you could seek to sell your
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to realize value, but you may be unable to do so in the absence of an established trading market for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not maintain a current and effective registration statement relating to the shares of common stock issuable upon exercise of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants, holders will only be able to exercise such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on a &#8220;cashless basis.&#8221; </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we do not maintain a current and effective registration statement relating to the shares of common stock issuable upon exercise of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants at the time that holders wish to exercise such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, they will only be able to exercise them on a &#8220;cashless basis,&#8221; provided
that an exemption from registration is available. As a result, the number of shares of common stock that holders will receive upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be fewer than it would have been had
such holder exercised his or her warrant for cash, and holders may be limited in their ability to immediately sell shares upon exercise, subject to volume or other securities law limitations. Further, if an exemption from registration is not
available, holders would not be able to exercise on a cashless basis and would only be able to exercise their <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants for cash if a current and effective registration statement relating to the
shares of common stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants is available. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A sale of a
substantial number of shares of our common stock, including any shares issuable upon exercise of any <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, may cause the price of our common stock to decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot predict what effect, if any, future sales of our shares in the public market or the availability of shares for sale will have on the market price of
our common stock. However, future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of any <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants issued in this offering or option
awards or upon settlement of restricted stock units or shares sold pursuant to our &#8220;at the market&#8221; equity offering program that we entered into on January&nbsp;22, 2026 with Leerink Partners LLC (the &#8220;Sale Agreement&#8221;), or the
perception that such sales may occur, could adversely affect the market price of our common stock. For example, 5,147,773 shares were issued upon exercise of our common warrants prior to March&nbsp;31, 2026, and 5,000,000 shares were sold pursuant
to the Sale Agreement during the quarter ended March&nbsp;31, 2026. We also expect that significant additional capital will be needed in the future to continue our planned operations. To raise capital, we may sell common stock, convertible
securities, or other equity securities in one or more transactions at prices and in a manner we determine from time to time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, including
the shares issuable upon exercise of the 47,487,573 common stock warrants that remaining outstanding as of March&nbsp;31, 2026, could reduce the market price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Participation in this offering by certain of our existing stockholders and their affiliated entities may reduce the public float for our common stock.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of our existing stockholders and their affiliated entities purchase shares of our common stock in this offering, such purchases would
reduce the available public float of our common stock because such purchasers would be restricted from selling such shares during the <FONT STYLE="white-space:nowrap">60-day</FONT> period following this offering and thereafter would be subject to
volume limitations pursuant to restrictions under applicable securities laws. As a result, any purchase of shares of our common stock by our existing stockholders and their affiliated entities in this offering will reduce the liquidity of our common
stock relative to what it would have been had these shares been purchased by investors that were not our stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in
the use of the net proceeds from this offering and may not use them effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the application of
the net proceeds to us from this offering, including for any of the purposes described in the section entitled &#8220;Use of Proceeds,&#8221; and you will not have the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. Because of the number and variability of factors that will determine our use of
the net proceeds to us from this offering, their ultimate use may vary substantially from their currently intended use. Our management might not apply net proceeds from this offering in ways that ultimately increase the value of your investment. The
failure by our management to apply these funds effectively could harm our business. Pending their use, we may invest the net proceeds from this offering in short-term, investment-grade, interest-bearing securities. These investments may not yield a
favorable return to our stockholders. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx122207_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We make &#8220;forward-looking statements&#8221; within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the
Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) in this prospectus supplement and the accompanying prospectus, including the documents that we incorporate by reference herein and therein. Our forward-looking statements
are subject to risks and uncertainties and include information about our current expectations and possible or assumed future results of our operations. When we use words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221;
&#8220;should,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221;
&#8220;forecast,&#8221; &#8220;projected,&#8221; &#8220;intend&#8221; or similar expressions, or make statements regarding our intent, belief, or current expectations, we are making forward-looking statements. Because these forward-looking
statements are based on estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual results could be materially different from the
anticipated future results, performance or achievements expressed or implied by any forward-looking statements. Such business, economic and competitive uncertainties include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of the initiation, progress, and expected results of our nonclinical studies, our clinical trials, and
our research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enroll patients in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs related to our nonclinical studies, our clinical trials, our research and development programs, and the
impact of inflationary pressures on such costs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to retain the continued service of our key executives and to identify, hire, and retain additional
qualified professionals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance product candidates into, and successfully complete, nonclinical studies and clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory filings and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commercialization of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability and the potential to successfully manufacture and supply our product candidates for clinical trials
and for commercial use, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing, coverage, and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our business model, strategic plans for our business, and product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our
technology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our potential need to obtain additional licenses of third-party technology that may not be available to us or are
available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enter into strategic arrangements and/or collaborations and to realize the potential benefits of
such arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding the market opportunity for our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding expenses, capital requirements, and needs for additional financing, and our ability to
obtain additional capital; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments relating to our competitors and our industry, including competing product candidates and therapies;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic downturns, inflation, fluctuating interest rates, changes in trade policies including tariffs or other
trade restrictions, or the threat of such actions, natural disasters, public health crises such as pandemics, political crises, government shutdowns, geopolitical events, or other macroeconomic conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the other risks more fully discussed in the &#8220;Risk Factors&#8221; section in this prospectus supplement, the
accompanying prospectus and the risk factors and cautionary statements described in other documents that we file from time to time with the SEC, specifically under &#8220;Risk Factors&#8221; and elsewhere in our most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and any subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other
factors not currently anticipated may also materially and adversely affect our results of operations, cash flows and financial position. Readers should not place undue reliance on any such forward-looking statements, which are based on information
available to us on the date of this report or, if made elsewhere, as of the date made. We do not undertake, and expressly disclaim, any intention to update or alter any statements whether as a result of new information, future events or otherwise
except as required by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx122207_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that we will receive net proceeds of approximately $&#8195;&#8195;&#8195; million (or approximately $&#8195;&#8195;&#8195; million if the
underwriters&#8217; option to purchase additional shares is exercised in full) from the sale of the shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants offered by us in this offering, based on the public offering
price of $&#8195;&#8195;&#8195;&#8195; per share of common stock and $&#8195;&#8195;&#8195; per <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant (which equals the price per share at which the shares of our common stock are being sold to
the public in this offering, minus $0.0001 per share of common stock), after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, and excluding the proceeds, if any, from the exercise of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants sold in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from this offering to advance our ongoing
and planned clinical trials and to develop and advance additional product candidates, as well as for working capital and general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assuming the full exercise of remaining outstanding common stock warrants, we currently expect that our existing cash and cash equivalents would be able to
fund operations into 2029. See &#8220;Prospectus Supplement Summary&#8212;Recent Developments&#8212;Warrant Exercises.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this
prospectus supplement, we cannot specify with certainty all of the particular uses of the proceeds, if any, from this offering. Accordingly, we will retain broad discretion over the use of any such proceeds. See the section titled &#8220;Risk
Factors&#8212;Risks Related to This Offering&#8212;We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pending the use of the proceeds from this offering, we intend to invest the proceeds in a variety of capital preservation investments, including which may
include interest-bearing, investment-grade securities, certificates of deposit or government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx122207_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering (or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in lieu thereof), your ownership interest
will be immediately diluted to the extent of the difference between the public offering price per share of our common stock (or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant in lieu thereof) and the pro forma net tangible book value per
share of our common stock immediately after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our historical net tangible book value as of March&nbsp;31, 2026 was approximately
$95.8&nbsp;million, or $1.27 per share. Our historical net tangible book value is the amount of our total tangible assets less our total liabilities. Net tangible book value per share of common stock represents net tangible book value divided by an
aggregate of 75,581,787 shares of our common stock outstanding as of March&nbsp;31, 2026. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After giving effect to our issuance and sale of
&#8195;&#8195;&#8195; shares of our common stock and &#8195;&#8195;&#8195; <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in this offering at the public offering price of $&#8195;&#8195;&#8195; per share and $ &#8195;&#8195;&#8195; per <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant (which equals the price per share at which the shares of our common stock are being sold to the public in this offering, minus $0.0001 per share of common stock), and after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma net tangible book value as of March&nbsp;31, 2026 would have been approximately $&#8195;&#8195;&#8195; million, or $&#8195;&#8195;&#8195; per share.
This represents an immediate increase in pro forma net tangible book value of $&#8195;&#8195;&#8195; per share to our existing stockholders and an immediate dilution of $&#8195;&#8195;&#8195; per share to investors purchasing securities in this
offering, as illustrated in the following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share as of March&nbsp;31, 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The dilution information discussed above assumes no exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants sold in this offering and is illustrative only. Investors who receive shares of our common stock upon the exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants offered hereby may experience additional dilution
depending on our net tangible book value at the time of exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the underwriters exercise in full their option to purchase additional shares, our
pro forma net tangible book value per share after this offering would be $&#8195;&#8195;&#8195;, representing an immediate increase in pro forma net tangible book value per share of $&#8195;&#8195;&#8195; to existing stockholders and immediate
dilution in pro forma net tangible book value per share of $&#8195;&#8195;&#8195; to new investors purchasing shares of common stock in this offering at the public offering price of $&#8195;&#8195;&#8195; per share, and after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of common stock that will be outstanding after
this offering is based on 75,581,787 shares of common stock outstanding as of March&nbsp;31, 2026 and excludes, in each case, as of March&nbsp;31, 2026: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">47,487,573 shares of common stock issuable upon the exercise of common warrants to purchase common stock
outstanding as of March&nbsp;31, 2026 at a weighted-average exercise price of $1.0846; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5,147,773 shares of common stock issued upon the exercise of common warrants prior to March&nbsp;31, 2026, at an
exercise price of $1.0846 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">38,448,034 shares of common stock issuable upon the exercise of
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase common stock outstanding as of March&nbsp;31, 2026 at a weighted-average exercise price of $0.0001; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">13,064,499 shares of common stock issuable upon the exercise of outstanding stock options under our EIP, with a
weighted-average exercise price of $5.05 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">589,803 shares of common stock issuable upon the vesting of outstanding restricted stock units;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,559,581 shares of common stock reserved for future equity award grants under the EIP; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,660,870 shares of common stock reserved for future issuance under our ESPP. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that options, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants or common warrants outstanding as of March&nbsp;31, 2026 have been or
are exercised, restricted stock units outstanding as of March&nbsp;31, 2026 have vested or vest, or other shares are issued, investors purchasing shares in this offering could experience further dilution. In addition, we may choose to raise
additional capital due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible
debt securities, the issuance of these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx122207_8"></A>DESCRIPTION OF SECURITIES WE ARE OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are offering shares of our common stock
in this offering. See the section titled &#8220;Description of Securities&#8221; in the accompanying prospectus for more information regarding our shares of common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of the material attributes and characteristics of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. The form of <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant will be provided to the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant purchasers in this offering and will be filed as an exhibit to a Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> filed in connection with this offering and incorporated by reference into the registration statement of which this prospectus supplement forms a part. The following summary is subject in all respects to the
provisions contained in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Duration and Exercise Price. </I></B>Each <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant entitles the holder thereof to purchase shares of our common stock at an exercise price equal to $0.0001 per share. Each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will be
exercisable at any time beginning on the date of issuance and will not expire. The number of shares of our common stock issuable upon exercise of each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant is subject to adjustment in the event
of stock dividends, stock splits, combinations, reclassifications or similar events affecting our common stock and the exercise price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exercisability</I></B>. The holder of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant may exercise the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant by delivering an exercise notice, completed and duly signed, and payment in cash of the exercise price for the number of shares of our common stock for which the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant is being exercised. The holder of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant may also satisfy its obligation to pay the exercise price through a &#8220;cashless
exercise,&#8221; in which the holder receives the net value of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant in shares of common stock determined according to the formula set forth in the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon a holder&#8217;s exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrant, we will issue the shares of common stock to which the holder is entitled pursuant to such exercise within three trading days after the exercise date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will not be entitled to exercise any portion of such
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant that, upon giving effect to such exercise, would cause the aggregate number of shares of our common stock beneficially owned by such holder (together with its affiliates and any other
persons whose beneficial ownership of common stock would be aggregated with the holder for purposes of Section&nbsp;13(d) or Section&nbsp;16 of the Exchange Act) to exceed 4.99% or 9.99%, as applicable, of the total number of then issued and
outstanding shares of common stock, as such percentage ownership is determined in accordance with the terms of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant and subject to such holder&#8217;s rights under the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant to increase or decrease such percentage to any other percentage not in excess of 19.99% upon at least 61 days&#8217; prior notice from such holder to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fundamental Transaction. </I></B>In the event of any fundamental transaction, as described in the <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants and generally including any merger with or into another entity, sale of all or substantially all of our assets, tender offer or exchange offer, a business combination resulting in another person acquiring more than 50% of our capital stock
or reclassification of our shares of common stock, then upon any subsequent exercise of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant, the holder will have the right to receive as alternative consideration, for each share of common
stock that would have been issuable upon such exercise immediately prior to the occurrence of such fundamental transaction, the number of shares of common stock of the successor or acquiring corporation of our company, if it is the surviving
corporation, and any additional consideration receivable upon or as a result of such transaction by a holder of the number of shares of common stock for which the warrant is exercisable immediately prior to such event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transferability. </I></B>Subject to applicable laws, a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant may be transferred at the option of
the holder upon surrender of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant to us together with the appropriate instruments of transfer and payment of funds sufficient to pay any transfer taxes (if applicable). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exchange Listing. </I></B>There is no trading market available for the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on any securities exchange or nationally recognized trading system. We do not intend to list the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on Nasdaq or any securities
exchange or nationally recognized trading system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will initially serve as the warrant agent under the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rights as a Stockholder</I></B><B>. </B>Except as otherwise provided in the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants or by virtue of such holder&#8217;s ownership of shares of our common stock, the holders of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants do not have the rights or privileges of
holders of our common stock, including any voting rights, until they exercise their <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx122207_9"></A>U.S. FEDERAL INCOME TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of U.S. federal income tax considerations to U.S. Holders and <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders
(each as defined below) of the ownership and disposition of the common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants issued pursuant to this offering. The discussion does not purport to be a complete analysis of all potential
tax considerations. The considerations of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws, are not discussed. This discussion is based on the
U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), Treasury Regulations promulgated under the Code, judicial decisions and published rulings and administrative pronouncements of the U.S. Internal Revenue Service (the
&#8220;IRS&#8221;), in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely
affect a holder of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court
will not take a contrary position to that discussed below regarding the tax considerations of the ownership and disposition of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion is limited to holders that hold our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants as a &#8220;capital
asset&#8221; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax considerations relevant to such holder&#8217;s particular circumstances,
including without limitation the alternative minimum tax and the effect of the Medicare contribution tax on net investment income. In addition, it does not address considerations relevant to holders who are subject to special rules, including,
without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. expatriates and former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants as part of a
hedge, straddle or other risk-reduction strategy or as part of a conversion transaction or other integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, insurance companies, or other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts or regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers, dealers or traders in currencies or securities, or other persons that elect to use a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting for their holdings in our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;controlled foreign corporations,&#8221; &#8220;passive foreign investment companies&#8221; and
corporations that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons deemed to sell our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants under the
constructive sale provisions of the Code; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that own, or have owned, actually or constructively, more than 5% of our common stock and/or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pension plans or funds, or an entity that is wholly owned by a pension plan or fund, including &#8220;qualified
foreign pension funds&#8221; as defined in Section&nbsp;897(l)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an entity or arrangement classified as a partnership for U.S. federal income tax purposes holds our common stock or
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level.
Accordingly, each partnership and each partner in such partnership holding our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants is urged to consult its tax advisor regarding the U.S. federal income tax considerations to it
of the ownership and disposition of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a &#8220;U.S. Holder&#8221; is any person that, for U.S. federal income tax
purposes, is or is treated as any of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation or other entity treated as a corporation for U.S. federal income tax purposes, created in, or
organized under the laws of the United States or any state thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust that (i)&nbsp;is subject to the primary supervision of a U.S. court and the control of one or more
&#8220;United States persons&#8221; (within the meaning of Section&nbsp;7701(a)(30) of the Code), or (ii)&nbsp;has a valid election in effect to be treated as a U.S. person for U.S. federal income tax purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">&#8220;Non-U.S.</FONT> Holder&#8221; is any beneficial owner of our common stock or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants that is neither a U.S. Holder nor an entity or arrangement treated as a partnership or other entity or arrangement treated as a pass-through entity for U.S. federal income tax purposes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. EACH INVESTOR IS URGED TO CONSULT ITS TAX ADVISOR WITH RESPECT TO THE APPLICATION
OF U.S. FEDERAL INCOME TAX LAWS TO ITS PARTICULAR SITUATION AS WELL AS ANY TAX CONSIDERATIONS OF THE OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK OR <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANTS ARISING UNDER THE U.S. FEDERAL ESTATE
OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Treatment of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although it is not entirely free from doubt, because the exercise price of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants is a nominal amount,
the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are generally expected to be treated as shares of our common stock for U.S. federal income tax purposes (and a holder is expected to be subject to the same tax considerations as if the
holder held shares of our common stock as discussed below). Accordingly, no gain or loss should be recognized upon exercise of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant (other than with respect to cash paid in lieu of a fractional
share), and the holding period of the shares of our common stock received upon exercise of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant should include the holding period of the <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrant. Similarly, the tax basis of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant should carry over to the shares of common stock received upon exercise, increased by the exercise price. Each U.S. Holder and <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is urged to consult its tax advisor regarding the U.S. federal income tax considerations to it of the ownership and disposition of the pre-funded warrants and the consequences upon a cashless
exercise of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant, including with respect to its holding period and tax basis in the shares of common stock received. The remainder of this discussion assumes that the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants will be treated as shares of our common stock for U.S. federal income tax purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Holders
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Distributions on Common Stock and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have no present intention to pay cash dividends on our common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. However, if we do make
distributions of cash or other property on our common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (other than certain distributions of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants), those
distributions will generally constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If the amount of such
distributions exceeds our current and accumulated earnings and profits, such excess will generally constitute a <FONT STYLE="white-space:nowrap">non-taxable</FONT> return of capital and will first be applied against and reduce, but not below zero, a
U.S. Holder&#8217;s adjusted tax basis in our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. Any excess will be treated as capital gain and will be treated as described below under the subsection titled
&#8220;U.S. Holders&#8212;Sale or Other Taxable Disposition of Common Stock or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends paid to a U.S. Holder of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants that is a taxable corporation will
generally qualify for the dividends received deduction if the requirements relating to the requisite holding period are satisfied. With certain exceptions, and provided certain holding period requirements are met, dividends we pay to a <FONT
STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder will generally constitute &#8220;qualified dividends&#8221; that currently are subject to tax at preferential long-term capital gains rates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sale or Other Taxable Disposition of Common Stock or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon a sale, taxable exchange or other taxable disposition of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, a U.S. Holder
will generally recognize capital gain or loss in an amount equal to the difference between (1)&nbsp;the amount realized upon such sale, taxable exchange or other taxable disposition and (2)&nbsp;such U.S. Holder&#8217;s tax basis in the common stock
or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. Such gain or loss will generally be treated as long-term capital gain or loss if the common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant is held by the U.S. Holder
for more than one year at the time of such sale, taxable exchange or other taxable disposition. Long-term capital gains recognized by certain <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. holders (including individuals) generally will
be subject to reduced rates of U.S. federal income tax. The deductibility of capital losses is subject to limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and
Backup Withholding </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information reporting requirements may apply to dividends paid to a U.S. Holder and to the proceeds of the sale, exchange or
other taxable disposition of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, unless the U.S. Holder is an exempt recipient (provided that, in the case of dividends paid to such exempt recipient, the exempt recipient
is not subject to backup withholding under Section&nbsp;3406 of the Code). Backup withholding may apply to such payments if the U.S. Holder fails to provide a taxpayer identification number or a certification of exempt status or has been notified by
the IRS that it is subject to backup withholding (and such notification has not been withdrawn). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts
withheld under the backup withholding rules may be allowed as a refund or a credit against a U.S. Holder&#8217;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Distributions on Common Stock and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have no present intention to pay cash dividends on our common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. However, if we do make
distributions of cash or other property on our common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (other than certain distributions of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants), those
distributions will generally constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If the amount of such
distributions exceeds our current and accumulated earnings and profits, such excess will generally constitute a <FONT STYLE="white-space:nowrap">non-taxable</FONT> return of capital and will first be applied against and reduce, but not below zero, a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#8217;s adjusted tax basis in our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. Any excess will be treated as capital gain and will be treated as described below
under the subsection titled <FONT STYLE="white-space:nowrap">&#8220;Non-U.S.</FONT> Holders&#8212;Sale or Other Taxable Disposition of Common Stock or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants
that are not effectively connected with such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#8217;s conduct of a trade or business in the United States will generally be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty, provided such <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder furnishes the applicable withholding agent with documentation required to claim benefits under such tax treaty (generally, a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or a successor form)). These certifications must be provided to the applicable withholding agent prior to the payment of dividends and must be updated periodically.
Each <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is urged to consult its tax advisor regarding U.S. federal withholding tax on distributions on our common stock or pre-funded warrants, including such
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#8217;s eligibility for benefits under any applicable income tax treaties and the availability of a refund on any excess U.S. federal tax withheld. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder are effectively connected with such
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a
permanent establishment in the United States to which such dividends are attributable), such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will generally be exempt from the U.S. federal withholding tax described above. To claim the
exemption, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must furnish to the applicable withholding agent a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> (or a successor form) certifying that the dividends are effectively
connected with such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#8217;s conduct of a trade or business within the United States. In general, any such effectively connected dividends will be subject to U.S. federal income tax on a net
income basis at the regular rates applicable to a U.S. person, unless a specific treaty exemption applies. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30%
(or such lower rate specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items. Each <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is urged to consult its tax advisor regarding the
U.S. federal income tax considerations of any distributions with respect to our common stock or pre-funded warrant, including any applicable tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sale or Other Taxable Disposition of Common Stock or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will generally not be subject to U.S. federal income or withholding tax on any gain realized upon the
sale or other taxable disposition of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#8217;s
conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment or fixed base in the United States to which
such gain is attributable); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual present in the
United States for 183 days or more during the taxable year of the disposition and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants constitute a U.S. real property
interest (&#8220;USRPI&#8221;) by reason of our status as a U.S. real property holding corporation (&#8220;USRPHC&#8221;) for U.S. federal income tax purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point above will generally be subject to U.S. federal income tax on a net income basis at the regular rates applicable to
U.S. persons, unless a specific treaty exemption applies. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a &#8220;branch profits tax&#8221; at a rate of 30% (or such lower rate specified by an
applicable income tax treaty) on such effectively connected gain, as adjusted for certain items. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gain described in the second bullet point above will
generally be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty), which may be offset by certain U.S.-source capital losses of a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder, provided such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with respect to such losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the third bullet point above, we believe we currently are not, and we do not anticipate becoming, a USRPHC. However, we cannot assure you that
we will not become a USRPHC. Even if we are or were to become a USRPHC, however, our common stock will not be treated as a USRPI if our common stock is &#8220;regularly traded&#8221; on an &#8220;established securities market&#8221; (as such terms
are defined by applicable Treasury </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Regulations) and such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, actually and constructively, 5% or less of our common stock or
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants throughout the shorter of the <FONT STYLE="white-space:nowrap">5-year</FONT> period ending on the date of the sale or other taxable disposition or such
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#8217;s holding period. No assurance can be provided that our common stock will be regularly traded on an established securities market for purposes of the rules described above. <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are urged to consult their tax advisors regarding the application of these rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is urged to consult its tax advisor regarding the U.S. federal income tax considerations of the
sale or other taxable disposition of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, including any applicable income tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup Withholding </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments of
dividends on our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants generally will not be subject to backup withholding provided the applicable withholding agent does not have actual knowledge or reason to know the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a U.S. person and the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder certifies its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status by furnishing a valid IRS Form W-8BEN, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> <FONT STYLE="white-space:nowrap">W-8EXP</FONT> or other applicable IRS form, or otherwise establishes an exemption.
Information returns are required to be filed with the IRS in connection with any distributions on our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder,
regardless of whether any tax was actually withheld. Copies of these information returns may also be made available under the provisions of an applicable treaty or agreement to the tax authorities of the country in which the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder resides or is established. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information reporting and, depending on the circumstances, backup
withholding generally will apply (at the applicable rate) to the proceeds of the sale or other taxable disposition of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants within the United States or conducted through
certain U.S.-related brokers, unless the applicable withholding agent receives the certification described above and does not have actual knowledge or reason to know that a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a U.S. person, or
such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder otherwise establishes an exemption. Proceeds of a disposition of our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants conducted through a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker that does not have certain enumerated relationships with the United States generally will not be subject to backup withholding or
information reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or
a credit against a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#8217;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Withholding Tax on Payments Made to Foreign Accounts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Withholding taxes may be imposed under Sections 1471 to 1474 of the Code and the rules and regulations promulgated thereunder (commonly referred to as
&#8220;FATCA&#8221;) on certain types of payments made to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial institutions and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a 30% withholding tax may be
imposed on dividends on our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants paid to a &#8220;foreign financial institution&#8221; or a <FONT STYLE="white-space:nowrap">&#8220;non-financial</FONT> foreign entity&#8221;
(each as defined in the Code), unless: (i)&nbsp;the foreign financial institution undertakes certain diligence, reporting and withholding obligations; (ii)&nbsp;the <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity either
certifies it does not have any &#8220;substantial United States owners&#8221; (as defined in the Code) or furnishes identifying information regarding each substantial United States owner; or (iii)&nbsp;the foreign financial institution or <FONT
STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to the diligence, reporting and withholding requirements in
(i)&nbsp;above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain &#8220;specified United States persons&#8221; or &#8220;United States
owned foreign entities&#8221; (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to noncompliant foreign financial institutions and certain other account holders. Foreign
financial institutions located in jurisdictions that have an intergovernmental agreement with the United States concerning FATCA may be subject to different rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under current Treasury Regulations, FATCA withholding could apply to gross proceeds from a sale or other
disposition of property of a type that can produce U.S.-source dividends. However, the U.S. Treasury Department has issued proposed regulations that, if finalized in their present form, would eliminate FATCA withholding on payments of gross
proceeds. Although these proposed regulations are not final and have not been adopted as final Treasury Regulations, the preamble to the proposed regulations provides that taxpayers generally may rely on the proposed regulations until final
regulations are issued. Accordingly, FATCA withholding generally is not expected to apply to gross proceeds from a sale or other disposition of the common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, although FATCA
withholding may continue to apply to other withholdable payments, such as dividends. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospective investors should consult their tax advisors regarding
the potential application of withholding under FATCA to their investment in our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx122207_10"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC, J.P. Morgan Securities LLC, Piper Sandler&nbsp;&amp; Co. and Cantor Fitzgerald&nbsp;&amp; Co. are acting as representatives of each of
the underwriters named below and as joint bookrunning managers for this offering. Subject to the terms and conditions set forth in the underwriting agreement among us and the representatives, we have agreed to sell to the underwriters, and each of
the underwriters has agreed, severally and not jointly, to purchase from us, the number of shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase shares of common stock set forth opposite its name below.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR><FONT STYLE="white-space:nowrap">Pre-Funded</FONT><BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have agreed, severally and not
jointly, to purchase all of the shares of common stock sold under the underwriting agreement if any of the shares of common stock are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may be increased or the underwriting agreement may be terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have agreed to
indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, subject to prior sale, when, as and
if issued to and accepted by them, subject to approval of legal matters by their counsel, including the validity of the shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, and subject to other conditions contained
in the underwriting agreement, such as the receipt by the underwriters of officers&#8217; certificates and legal opinions. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in
part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discounts and Commissions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The representatives
have advised us that the underwriters propose initially to offer the shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to the public at the initial public offering price set forth on the cover page of this
prospectus supplement and to dealers at that price less a concession not in excess of $&#8195;&#8195;&#8195;&#8195;per share or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. After the initial offering of the shares of common stock and <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants, the public offering price, concession or any other term of this offering may be changed by the representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows the initial public offering price, underwriting discounts and commissions and proceeds, before expenses, to us. The information
assumes either no exercise or full exercise by the underwriters of their option to purchase additional shares of our common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR><FONT STYLE="white-space:nowrap">Pre-Funded</FONT><BR>Warrant</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With<BR>Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts
and commissions referred to above, will be approximately $&#8195;&#8195;&#8195;&#8195;&#8195;. We have agreed to reimburse the underwriters for certain of their expenses in an amount not to exceed $40,000 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted an
option to the underwriters, exercisable for 30 days after the date of this prospectus supplement, to purchase up to&#8195;&#8195;&#8195;&#8195;additional shares of common stock at the initial public offering price, less underwriting discounts and
commissions. If the underwriters exercise this option, each underwriter will be obligated, subject to the conditions contained in the underwriting agreement, to purchase a number of additional shares of common stock proportionate to that
underwriter&#8217;s initial amount reflected in the above table. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and our executive officers and directors have agreed not to sell or transfer any shares of our capital stock or securities convertible into or exchangeable
or exercisable for such capital stock, for 60 days after the date of this prospectus supplement without first obtaining the written consent of the representatives on behalf of the underwriters. Specifically, we and these other persons have agreed,
with certain customary exceptions, not to directly or indirectly, offer, sell, contract to sell, pledge, lend, hedge or otherwise dispose of (or enter into any transaction which is designed to, or might reasonably be expected to, result in the
disposition (whether by actual disposition or effective economic disposition due to cash settlement or otherwise) by the undersigned or any affiliate of the undersigned or any person in privity with the undersigned or any affiliate of the
undersigned), directly or indirectly, including the filing (or participation in the filing) of a registration statement with the SEC in respect of, or establish or increase a put equivalent position or liquidate or decrease a call equivalent
position within the meaning of Section&nbsp;16 of the Exchange Act, and the rules and regulations of the SEC promulgated thereunder with respect to, any shares of our capital stock or any securities convertible into, or exercisable or exchangeable
for, such capital stock, or publicly announce an intention to effect any such transaction The <FONT STYLE="white-space:nowrap">lock-up</FONT> provisions apply to common stock and to securities convertible into or exchangeable or exercisable for
common stock. They also apply to common stock owned now or acquired later by the person executing the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement or for which the person executing the <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreement later acquires the power of disposition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing restrictions shall not apply to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers to the Company in connection with (A) the termination of such stockholder&#8217;s employment or (B)
pursuant to agreements under which the Company has the option to repurchase such shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the exercise of options or purchases under any Company stock incentive plan or stock purchase plan, provided
that the underlying shares remain subject to the restrictions herein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the exercise of pre-funded warrants or other outstanding Company warrants into shares of common stock, provided
that such shares remain subject to the restrictions herein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers to the Company to cover tax withholdings upon vesting of any equity award under any Company stock
incentive plan or stock purchase plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers by operation of law pursuant to a court order or settlement agreement related to the dissolution of a
marriage or civil union, provided that the transferee agrees to be bound by the restrictions herein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the establishment of a trading plan under Rule 10b5-1, provided that such trading plan does not provide for any
transfers during the lock-up period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sales or transfers pursuant to a Rule 10b5-1 trading plan entered into prior to the date of this prospectus
supplement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers pursuant to a bona fide third-party tender offer, merger, consolidation or other change of control
transaction made to all holders and approved by the Company&#8217;s board of directors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Select Market Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;STTK.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization, Short Positions and Penalty Bids </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until the distribution of the shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants is completed, SEC rules may limit
underwriters and selling group members from bidding for and purchasing our common stock. However, the representatives may engage in transactions that stabilize the price of the common stock, such as bids or purchases to peg, fix or maintain that
price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this offering, the underwriters may purchase and sell our common stock in the open market. These transactions may include short
sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in this offering.
&#8220;Covered&#8221; short sales are sales made in an amount not greater than the underwriters&#8217; option to purchase additional shares and/or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants described above. The underwriters may
close out any covered short position by either exercising their option to purchase additional shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants or purchasing shares in the open market. In determining the source of shares to close
out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the option to purchase additional
shares or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants granted to them under the underwriting agreement described above. &#8220;Naked&#8221; short sales are sales in excess of such option. The underwriters must close out any naked
short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our common stock in the open market after pricing that
could adversely affect investors who purchase in this offering. Stabilizing transactions consist of various bids for or purchases of shares of common stock made by the underwriters in the open market prior to the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount
received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similar to other purchase transactions, the underwriters&#8217; purchases to cover the syndicate short sales may have the effect of raising or maintaining the
market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. The underwriters
may conduct these transactions on the Nasdaq Global Select Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described
above may have on the price of our common stock. In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these transactions or that these transactions, once commenced, will not be
discontinued without notice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means, such as <FONT
STYLE="white-space:nowrap">e-mail.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters and certain of their affiliates are full service financial institutions engaged in various activities, which may include securities trading,
commercial and investment banking, financial advisory, investment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
management, investment research, principal investment, hedging, financing and brokerage activities. Some of the underwriters and certain of their affiliates may in the future engage in investment
banking and other commercial dealings in the ordinary course of business with us and our affiliates, for which they may in the future receive customary fees, commissions and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of investments and
actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities may involve
securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and
may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in the European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area (each, a &#8220;Relevant State&#8221;), no shares of common stock or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares of common stock and <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State,
all in accordance with the Prospectus Regulation, except that offers of the shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants may be made to the public in that Relevant State at any time under the following
exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined under the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus
Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I> that no such offer of the shares of common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants shall require us or any of the
representatives to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to the shares of common stock and <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares of common stock or
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to be offered so as to enable an investor to decide to purchase any shares of common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, and the expression
&#8220;Prospectus Regulation&#8221; means Regulation (EU) 2017/1129, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each person in a Relevant State who receives any communication in
respect of, or who acquires any shares of common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants under, the offering contemplated hereby will be deemed to have represented, warranted and agreed to and with each of the
underwriters and their affiliates and to us that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) it is a qualified investor within the meaning of the Prospectus Regulation; and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) in the case of any shares of common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants acquired by it as a
financial intermediary, as that term is used in Article 5 of the Prospectus Regulation, (i)&nbsp;the shares of common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants acquired by it in the offering have not been acquired on a <FONT
STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any Relevant State other than </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
qualified investors, as that term is defined in the Prospectus Regulation, or have been acquired in other circumstances falling within the points (a)&nbsp;to (d) of Article 1(4) of the Prospectus
Regulation and the prior consent of the representative has been given to the offer or resale; or (ii)&nbsp;where the shares of common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants have been acquired by it on behalf of persons
in any Relevant State other than qualified investors, the offer of those shares of common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to it is not treated under the Prospectus Regulation as having been made to such persons.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, the underwriters and their affiliates, and others will rely upon the truth and accuracy of the foregoing representation, acknowledgement and
agreement. Notwithstanding the above, a person who is not a qualified investor and who has notified the representative of such fact in writing may, with the prior consent of the representative, be permitted to acquire shares of common stock or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants in the offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in the United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and any other material in relation to the securities described herein is only being distributed to, and is only directed at, and any investment
or investment activity to which this prospectus relates is available only to, and will be engaged in only with persons who are (i)&nbsp;persons having professional experience in matters relating to investments who fall within the definition of
investment professionals in Article 19(5) of the FPO; or (ii)&nbsp;high net worth entities falling within Article 49(2)(a) to (d)&nbsp;of the FPO; (iii)&nbsp;outside the UK; or (iv)&nbsp;persons to whom an invitation or inducement to engage in
investment activity (within the meaning of Section&nbsp;21 of the Financial Services and Markets Act 2000, or &#8220;FSMA&#8221; ) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be
communicated (all such persons together being referred to as &#8220;Relevant Persons&#8221;). The securities are only available in the UK to, and any invitation, offer or agreement to purchase or otherwise acquire the securities will be engaged in
only with, the Relevant Persons. This prospectus and its contents are confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other person in the UK. Any person in the UK that is
not a Relevant Person should not act or rely on this prospectus or any of its contents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No shares of common stock or
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants have been offered or will be offered pursuant to the offering to the public in the UK prior to the publication of a prospectus in relation to the shares of common stock and <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants which has been approved by the Financial Conduct Authority in the UK in accordance with the UK Prospectus Regulation and the FSMA, except that offers of the shares of common stock or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants may be made to the public in the UK at any time: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a &#8220;qualified investor&#8221; as defined under Article 2(e) of the UK
Prospectus Regulation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2(e) of the
UK Prospectus Regulation), subject to obtaining the prior consent of the underwriters for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Section&nbsp;86 of the FSMA, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I> that no such offer of the shares of common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants shall require us or any
representative to publish a prospectus pursuant to Section&nbsp;85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an &#8220;offer to the public&#8221;
in relation to the shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any shares
of common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to be offered so as to enable an investor to decide to purchase or subscribe for any shares of common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants
and the expression &#8220;UK Prospectus Regulation&#8221; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. Each person in the UK who acquires any shares of common stock or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants in the offer or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with us, the underwriters and their affiliates that it meets the criteria outlined in
this section. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in Canada </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants may be sold only to purchasers purchasing, or deemed to be
purchasing, as principal that are accredited investors, as defined in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;45-106&nbsp;Prospectus</FONT> Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted
clients, as defined in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;31-103&nbsp;Registration</FONT> Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares of common stock or
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus
supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s
province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National <FONT STYLE="white-space:nowrap">Instrument&nbsp;33-105&nbsp;Underwriting</FONT> Conflicts
<FONT STYLE="white-space:nowrap">(NI&nbsp;33-105),&nbsp;the</FONT> underwriters are not required to comply with the disclosure requirements of <FONT STYLE="white-space:nowrap">NI&nbsp;33-105&nbsp;regarding</FONT> underwriter conflicts of interest in
connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in the Dubai International Financial Centre </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority, or the
&#8220;DFSA&#8221;. This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for
reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The securities to which this
prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the contents of this prospectus
you should consult an authorized financial advisor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (i)&nbsp;to &#8220;professional
investors&#8221; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (ii)&nbsp;in other circumstances which do not result in the document being a &#8220;prospectus&#8221; as defined
in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to our securities
has been or may be issued or has been or may be in the possession of any person for the purposes of issuance, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong
Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to our securities which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; as
defined in the Securities and Futures Ordinance and any rules made under that Ordinance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in Singapore </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or
material in connection with the offer or sale, or invitation for subscription or purchase, of the securities may not be circulated or distributed, nor may the securities be offered or sold, or be made the subject of an invitation for subscription or
purchase, whether directly or indirectly, to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore, or the &#8220;SFA&#8221;, (ii) to a
relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the
conditions of, any other applicable provision of the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where the securities are subscribed or purchased under Section&nbsp;275 of the SFA by a
relevant person which is (a)&nbsp;a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more
individuals, each of whom is an accredited investor; or (b)&nbsp;a trust (where the trustee is not an accredited investor) the sole purpose of which is to hold investments and each beneficiary of the trust is an individual who is an accredited
investor, securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#8217; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that
trust has acquired the securities pursuant to an offer made under Section&nbsp;275 of the SFA except: (i)&nbsp;to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer
referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; (ii)&nbsp;where no consideration is or will be given for the transfer; (iii)&nbsp;where the transfer is by operation of law; (iv)&nbsp;as specified in Section&nbsp;276(7)
of the SFA; or (v)&nbsp;as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Solely for the purposes of its obligations pursuant to Section&nbsp;309B of the SFA, we have determined, and hereby notify all relevant persons (as defined in
the CMP Regulations 2018), that the shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are &#8220;prescribed capital markets products&#8221; (as defined in the CMP Regulations 2018) and Excluded Investment
Products (as defined in MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment Products and MAS Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on Recommendations on Investment Products). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in Switzerland </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is not intended to constitute an offer or solicitation to purchase or invest in our securities. Our securities may not be publicly offered,
directly or indirectly, in Switzerland within the meaning of the Swiss Financial Services Act, or the &#8220;FinSA&#8221;, and no application has or will be made to admit our securities to trading on any trading venue (exchange or multilateral
trading facility) in Switzerland. Neither this prospectus nor any other offering or marketing material relating to our securities constitutes a prospectus pursuant to the FinSA, and neither this prospectus nor any other offering or marketing
material relating to our securities may be publicly distributed or otherwise made publicly available in Switzerland. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx122207_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gibson, Dunn&nbsp;&amp; Crutcher LLP, San Francisco, California will pass upon the validity of the shares offered hereby. Certain legal matters in connection
with this offering will be passed upon for the underwriters by Latham&nbsp;&amp; Watkins LLP, New York, New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx122207_12"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of Shattuck Labs, Inc. as of December&nbsp;31, 2025 and 2024, and for the years then ended, have been incorporated by reference
herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx122207_13"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. We also filed a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> including exhibits, under the Securities Act with respect to the securities offered by this prospectus supplement and the accompanying prospectus. This prospectus supplement and the accompanying prospectus are
a part of that registration statement, but do not contain all of the information included in the registration statement or the exhibits. You can find our public filings with the SEC on the internet at a web site maintained by the SEC located at
www.sec.gov. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx122207_14"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference the information and reports we file with it, which means that we can disclose important information to you by
referring you to these documents. The information incorporated by reference is an important part of this prospectus supplement, and information that we file after the date hereof with the SEC will automatically update and supersede the information
already incorporated by reference. We are incorporating by reference the documents listed below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1680367/000162828026014989/sttk-20251231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2025, filed with the SEC on March&nbsp;
5, 2026 (and any portions of our Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1680367/000119312526146293/d134407ddef14a.htm">Schedule 14A</A> filed on April&nbsp;8, 2026 that are
incorporated by reference therein); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1680367/000162828026031661/sttk-20260331.htm">Form
 <FONT STYLE="white-space:nowrap">10-Q</FONT></A> for the quarter ended March&nbsp;31, 2026, filed with the SEC on May&nbsp;7, 2026; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1680367/000119312526019682/d59331d8k.htm">January&nbsp;22,
 2026</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1680367/000119312526039488/d76999d8k.htm">February&nbsp;
5, 2026</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1680367/000119312526253784/d149753d8k.htm">June&nbsp;
2, 2026 </A>and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1680367/000119312526263831/d120796d8k.htm">June&nbsp;9, 2026</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our securities contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1680367/000119312520263847/d939403d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> filed with the SEC on October&nbsp;5, 2020, including any amendments or reports filed for the purposes of updating this description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All documents we file with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act shall be deemed incorporated by reference in this
prospectus and to be a part of this prospectus supplement from the date of filing of those documents, with the exception of any portion of any report or document that is not deemed &#8220;filed&#8221; under such provisions on or after the date of
this prospectus supplement, until the earlier of the date on which: (1)&nbsp;all of the securities registered under the registration statement have been sold; or (2)&nbsp;the registration statement of which this prospectus supplement is a part has
been withdrawn. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under no circumstances will any information filed under Items 2.02 or 7.01 of Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> be deemed incorporated herein by reference unless such Form <FONT STYLE="white-space:nowrap">8-K</FONT> expressly provides to the contrary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon written or oral request, we will provide without charge to each person to whom a copy of the prospectus supplement is delivered a copy of the documents
incorporated by reference herein (other than exhibits to such documents unless such exhibits are specifically incorporated by reference herein). You may request a copy of these filings, at no cost, by writing, calling or emailing us at the contact
information set forth below. We have not authorized anyone to provide you with any information that differs from that contained in this prospectus supplement. Accordingly, we take no responsibility for any other information that others may give you.
You should not assume that the information in this prospectus supplement is accurate as of any date other than the date of the front cover of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Shattuck Labs, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>500
W. 5th Street, Suite 1200 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Austin, TX 78701 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">(512)&nbsp;900-4690</FONT> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g122207g41w67.jpg" ALT="LOGO" STYLE="width:4.19in;height:1.27in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>PREFERRED STOCK </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>DEBT
SECURITIES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>WARRANTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may issue, in one or more series or classes, up to $200,000,000 in aggregate principal amount of our common stock,
preferred stock, debt securities, warrants and/or units, at prices and on terms that we will determine at the time of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
may offer these securities through agents, underwriters or dealers or directly to investors. See &#8220;Plan of Distribution&#8221; in this prospectus. This prospectus provides you with a general description of the securities we may offer. Each time
we offer securities, we will provide specific terms of the securities offered in a supplement to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus
supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. We may not sell any securities under this prospectus without delivery of the applicable prospectus supplement. If information
in any prospectus supplement is inconsistent with the information in this prospectus, then the information in that prospectus supplement will apply and will supersede the information in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus, the applicable prospectus supplement and any related free writing prospectus carefully, as well as any
documents incorporated by reference, before you invest in any of the securities being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our shares of common stock are listed on
The Nasdaq Global Select Market under the symbol &#8220;STTK.&#8221; The last reported sale price of our common stock on The Nasdaq Global Select Market on January&nbsp;12, 2026 was $4.59 per share. We recommend that you obtain current market
quotations for our common stock prior to making an investment decision. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the
heading </B><B><I>&#8220;</I></B><B><A HREF="#tx122207_4">Risk Factors</A>&#8221; contained in this prospectus beginning on page 5 and any applicable prospectus supplement, and under similar headings in the other documents that are incorporated by
reference into this prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or
disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus dated January 21, 2026 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc1"></A>Table of Contents </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_2">SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_3">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_6">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_7">SECURITIES WE MAY OFFER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_8">DESCRIPTION OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_9">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_10">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_11">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_12">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx122207_13">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx122207_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is a part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities
and Exchange Commission (the &#8220;SEC&#8221; or the &#8220;Commission&#8221;) utilizing a &#8220;shelf&#8221; registration process. Under this shelf registration process, we may sell any combination of the securities described in this prospectus
in one or more offerings up to a total dollar amount of $200,000,000. This prospectus provides you with a general description of the securities we may offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each time we sell securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the
terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we
may authorize to be provided to you may also add, update or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus. You should carefully read both this prospectus and any
prospectus supplement together with additional information under the headings &#8220;Where You Can Find Additional Information&#8221; and &#8220;Incorporation of Certain Information by Reference.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not authorized anyone to provide you with any information other than that contained or incorporated by reference in this prospectus
and any applicable prospectus supplement, along with the information contained in any free writing prospectuses we have authorized for use in connection with a specific offering. We take no responsibility for, and can provide no assurance as to the
reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. This prospectus, any applicable
supplement to this prospectus or any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, any
applicable supplement to this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation
in such jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not assume that the information contained in this prospectus, any applicable prospectus supplement or
any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document
incorporated by reference, even though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered, or securities are sold, on a later date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context otherwise requires, references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Shattuck Labs,&#8221;
&#8220;Shattuck,&#8221; or the &#8220;Company&#8221; refer to Shattuck Labs, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx122207_2"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, including the documents that we incorporate by reference, contains &#8220;forward-looking statements&#8221; within the
meaning of Section&nbsp;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements, other than statements
of historical facts contained in this prospectus, including statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, financing needs, plans or intentions relating to acquisitions, business trends
and other information referred to in the section entitled &#8220;Risk Factors&#8221; in this prospectus and the sections entitled &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations&#8221; in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as may be updated by subsequent annual, quarterly and other reports, which is incorporated by reference herein, are
forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221;
&#8220;might,&#8221; &#8220;will,&#8221; &#8220;objective,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;design,&#8221;
&#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;target,&#8221; &#8220;forecast,&#8221; or the negative of these terms, and similar expressions intended to identify
forward-looking statements. Forward-looking statements are not historical facts and reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should
not place undue reliance on these forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are a number of risks, uncertainties and other important factors that
could cause our actual results to differ materially from the forward-looking statements contained in this prospectus and incorporated by reference herein. Such risks, uncertainties and other important factors include, among others, the following
risks, uncertainties and factors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of the initiation, progress, and expected results of our nonclinical studies, our clinical trials, and
our research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enroll patients in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs related to our nonclinical studies, our clinical trials, our research and development programs, and the
impact of inflationary pressures on such costs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to retain the continued service of our key executives and to identify, hire, and retain additional
qualified professionals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance product candidates into, and successfully complete, nonclinical studies and clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory filings and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commercialization of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability and the potential to successfully manufacture and supply our product candidates for clinical trials
and for commercial use, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing, coverage, and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our business model, strategic plans for our business, and product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our
technology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our potential need to obtain additional licenses of third-party technology that may not be available to us or are
available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enter into strategic arrangements and/or collaborations and to realize the potential benefits of
such arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding the market opportunity for our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding expenses, capital requirements, and needs for additional financing, and our ability to
obtain additional capital; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments relating to our competitors and our industry, including competing product candidates and therapies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic downturns, inflation, fluctuating interest rates, changes in trade policies including tariffs or other
trade restrictions, or the threat of such actions, natural disasters, public health crises such as pandemics, political crises, government shutdowns, geopolitical events, or other macroeconomic conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties, including those listed or incorporated by reference in &#8220;Risk Factors.&#8221;
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be other factors that may cause our actual results to differ materially from the forward-looking statements,
including factors disclosed in &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our most recent Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> and subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> which are incorporated by reference herein. You should evaluate all forward-looking statements made in this
prospectus in the context of these risks and uncertainties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These factors should not be construed as exhaustive and should be read in
conjunction with the other cautionary statements that are included in this prospectus, any accompanying prospectus supplement, information incorporated by reference herein or therein, and any related free-writing prospectus. In addition, we cannot
assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. All forward-looking
statements contained in this prospectus are made as of the date of hereof and we undertake no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx122207_3"></A>THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. We are
developing a potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antibody for the treatment of inflammatory bowel disease and other inflammatory and immune-mediated diseases. Our expertise in
protein engineering and the development of novel tumor necrosis factor receptor therapeutics come together in our lead program, <FONT STYLE="white-space:nowrap">SL-325,</FONT> which we believe could be a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> death receptor 3 antagonist antibody. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in 2016 in the State of Delaware. Our principal executive offices are located at 500 W. 5th Street, Suite 1200, Austin, TX
78701 and our telephone number is (512) <FONT STYLE="white-space:nowrap">900-4690.</FONT> Our website is <I>www.shattucklabs.com</I>. The information on, or that can be accessed through, our website is not part of this prospectus and is not
incorporated by reference herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx122207_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves risks. You should carefully consider the risks, uncertainties and other factors described in our most
recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as supplemented and updated by subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Current Reports on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> that we have filed or will file with the SEC, and in other documents which are incorporated by reference into this prospectus, as well as the risk factors and other information contained in or incorporated
by reference into any accompanying prospectus supplement, before investing in any of our securities. Our business, financial condition, results of operations, cash flows or prospects could be materially and adversely affected by any of these risks.
The risks and uncertainties described in the documents incorporated by reference herein are not the only risks and uncertainties that you may face. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information about our SEC filings, please see &#8220;Where You Can Find Additional Information&#8221; and &#8220;Incorporation of
Certain Information by Reference.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx122207_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. Unless otherwise specified in
a prospectus supplement accompanying this prospectus, the net proceeds from the sale by us of the securities to which this prospectus relates will be used to advance our ongoing and planned clinical trials and to develop and advance additional
product candidates, as well as for working capital and general corporate purposes. We may also use a portion of the proceeds to license, acquire, or invest in complementary businesses, technology, products, or assets. However, we have no current
commitments to do so. Our expected use of proceeds from the sale of the securities offered hereby represents our current intentions based on our present plans and business condition. As of the date of this prospectus, we cannot predict with
certainty all of the particular uses for the proceeds to be received from the sale of the securities offered hereby or the amounts that we will actually spend on the uses set forth above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending the use of the proceeds from this offering, we may invest the proceeds in a variety of capital preservation investments, including
interest-bearing, investment-grade securities, certificates of deposit, or government securities. When we offer and sell the securities to which this prospectus relates, the prospectus supplement related to such offering will set forth our intended
use of the proceeds, if any, received from the sale of such securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx122207_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and future earnings, if
any, to fund the operations and the further development and expansion of our business. We have no present intention to pay cash dividends on our common stock. Any determination to pay dividends to holders of our common stock will be at the
discretion of our board of directors (the &#8220;Board&#8221;) and will depend on many factors, including our financial condition, results of operations, liquidity, earnings, projected capital and other cash requirements, legal requirements,
restrictions in the agreements governing any indebtedness we may enter into, our business prospects, and other factors that our Board deems relevant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx122207_7"></A>SECURITIES WE MAY OFFER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains summary descriptions of the securities we may offer from time to time. These summary descriptions are not meant to be
complete descriptions of each security. The particular terms of any security will be described in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx122207_8"></A>DESCRIPTION OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of
the material terms of our capital stock, as well as other material terms of our amended and restated certificate of incorporation (&#8220;certificate of incorporation&#8221;) and amended and restated bylaws (&#8220;bylaws&#8221;) and certain
provisions of Delaware law. This summary does not purport to be complete and is qualified in its entirety by the provisions of our certificate of incorporation and our bylaws. For more information on how you can obtain our certificate of
incorporation and our bylaws, see the heading &#8220;Where You Can Find Additional Information.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock
consists of 300,000,000 shares of common stock, $0.0001 par value per share, and 10,000,000 shares of &#8220;blank check&#8221; preferred stock, $0.0001 par value per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of
incorporation authorizes the issuance of up to 300,000,000 shares of our common stock. All outstanding shares of our common stock are validly issued, fully paid and nonassessable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of our common stock are entitled to one vote per share on all matters submitted to a vote of stockholders, and our certificate of
incorporation does not provide for cumulative voting in the election of directors. The holders of our common stock will receive ratably any dividends declared by our Board out of funds legally available therefor. In the event of our liquidation,
dissolution or <FONT STYLE="white-space:nowrap">winding-up,</FONT> the holders of our common stock will be entitled to share ratably in all assets remaining after payment of or provision for any liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of our
certificate of incorporation, our Board has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in
each such series, to fix the dividend, voting and other rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of
any such series, but not below the number of shares of such series then outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may authorize the issuance of preferred
stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other
corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control and may adversely affect the market price of our common stock and the voting and other rights of the holders of our common
stock. We have no current plans to issue any shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Our Certificate of Incorporation, Bylaws and Delaware
Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and our bylaws include a number of provisions that may have the effect of delaying, deferring or
preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our Board rather than pursue
<FONT STYLE="white-space:nowrap">non-negotiated</FONT> takeover attempts. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Issuance of undesignated preferred stock</B>: Under our certificate of incorporation, our Board has the
authority, without further action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our Board. The existence of authorized but
unissued shares of preferred stock enables our Board to make it more difficult to attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Classified board</B>: Our certificate of incorporation establishes a classified Board consisting of three
classes of directors, with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. This provision
may have the effect of delaying a change in control of our Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Election and removal of directors and board vacancies</B>: Our certificate of incorporation provides that
directors will be elected by a plurality vote. Our certificate of incorporation and bylaws also provide that our Board has the right to increase or decrease the size of the Board and to fill vacancies on the Board. Directors may be removed only for
cause by the affirmative vote of the holders of at least 66 2/3% of the votes that all our stockholders would be entitled to cast in an annual election of directors. Only our Board is authorized to fill vacant directorships. In addition, the number
of directors constituting our Board may be set only by resolution adopted by a majority vote of the directors then in office. These provisions prevent stockholders from increasing the size of our Board and gaining control of our Board by filling the
resulting vacancies with its own nominees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Requirements for advance notification of stockholder nominations and proposals</B>: Our bylaws establish
advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors that specify certain requirements as to the timing, form and content of a stockholder&#8217;s notice. Business that may be
conducted at an annual meeting of stockholders will be limited to those matters properly brought before the meeting. These provisions may make it more difficult for our stockholders to bring matters before our annual meeting of stockholders or to
nominate directors at annual meetings of stockholders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>No written consent of stockholders</B>: Our certificate of incorporation provides that all stockholder actions
be taken by a vote of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would
prevent the amendment of our bylaws or removal of directors by our stockholders without holding a meeting of stockholders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>No stockholder ability to call special meetings</B>: Our certificate of incorporation and bylaws provide that
only our Board may be able to call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Amendments to certificate of incorporation and bylaws</B>: Any amendment to our certificate of incorporation
must be approved by a majority of our Board as well as, if required by law or our certificate of incorporation, a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to
vote thereon as a class, except that the amendment of provisions to Board classification, stockholder action, certificate amendments, and liability of directors must be approved by not less than 66 2/3% of the outstanding shares entitled to vote on
the amendment, voting together as a single class. Any amendment to our bylaws will be required to be approved by either a majority of our Board or not less than 66 2/3% of the outstanding shares entitled to vote on the amendment, voting together as
a single class. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions are designed to enhance the likelihood of continued stability in the composition of
our Board and its policies, to discourage certain types of transactions that may involve an actual or threatened acquisition of our Company and to reduce our vulnerability to an unsolicited acquisition proposal. We also designed these provisions to
discourage certain tactics that may be used in proxy fights. However, these provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they may also reduce fluctuations in the market price
of our shares that could result from actual or rumored takeover attempts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Delaware General Corporation Law Section&nbsp;203 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a Delaware corporation, we are also subject to the anti-takeover provisions of Section&nbsp;203 of the Delaware General Corporation Law (the
&#8220;DGCL&#8221;), which prohibits a Delaware corporation from engaging in a business combination specified in the statute with an interested stockholder (as defined in the statute) for a period of three years after the date of the transaction in
which the person first becomes an interested stockholder, unless the business combination is approved in advance by a majority of the independent directors or by the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the
outstanding disinterested shares. The application of Section&nbsp;203 of the DGCL could also have the effect of delaying or preventing a change of control of us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Exclusive Forum Selection Clause </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive
forum to the fullest extent permitted by law for: (1)&nbsp;any derivative action or proceeding brought on our behalf; (2)&nbsp;any action asserting a breach of fiduciary duty owed by any director, officer or other employee to us or our stockholders;
(3)&nbsp;any action asserting a claim against us or any director or officer or other employee arising pursuant to the DGCL; (4)&nbsp;any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or
(5)&nbsp;any other action asserting a claim that is governed by the internal affairs doctrine, shall be the Court of Chancery of the State of Delaware (or another state court or the federal court located within the State of Delaware if the Court of
Chancery does not have or declines to accept jurisdiction), in all cases subject to the court&#8217;s having jurisdiction over indispensable parties named as defendants. In addition, our certificate of incorporation provides that the federal
district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act but the forum selection provisions will not apply to claims brought to enforce a duty or
liability created by the Exchange Act. Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may have the effect of
imposing additional costs on stockholders in pursuing any such claims or limiting a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes, which may discourage lawsuits against us or our directors or
officers. Although our certificate of incorporation contains the choice of forum provisions described above, it is possible that a court could find that such provisions are inapplicable for a particular claim or action or that such provisions are
unenforceable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Equiniti Trust Company, LLC serves as the transfer agent and registrar for our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on
The Nasdaq Global Select Market under the symbol &#8220;STTK.&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Debt Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The paragraphs below describe the general terms and provisions of the debt securities we may issue. When we offer to sell a particular series
of debt securities, we will describe the specific terms of the securities in a supplement to this prospectus, including any additional covenants or changes to existing covenants relating to such series. The prospectus supplement also will indicate
whether the general terms and provisions described in this prospectus apply to a particular series of debt securities. You should read the actual indenture if you do not fully understand a term or the way we use it in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we issue debt securities at a discount from their principal amount, then, for purposes of calculating the aggregate initial offering price
of the offered securities issued under this prospectus, we will include only the initial offering price of the debt securities and not the principal amount of the debt securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have summarized below the material provisions of the indenture, or indicated which
material provisions will be described in the related prospectus supplement. The prospectus supplement relating to any particular securities offered will describe the specific terms of the securities, which may be in addition to or different from the
general terms summarized in this prospectus. We have included the form of the indenture as an exhibit to our registration statement of which this prospectus is a part, and it is incorporated into this prospectus by reference. Because the summary in
this prospectus and in any prospectus supplement does not contain all of the information that you may find useful, you should read the documents relating to the securities that are described in this prospectus or in any applicable prospectus
supplement. Please read &#8220;Where You Can Find Additional Information&#8221; in this prospectus to find out how you can obtain a copy of those documents. References below to an &#8220;indenture&#8221; are references to the indenture, as
supplemented, under which a particular series of debt securities is issued. As used under this caption, the term &#8220;debt securities&#8221; includes the debt securities being offered by this prospectus and all other debt securities issued by us
under the indenture. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">does not limit the amount of debt securities that we may issue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allows us to issue debt securities in one or more series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">does not require us to issue all of the debt securities of a series at the same time; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allows us to reopen a series to issue additional debt securities without the consent of the holders of the debt
securities of such series. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement for each offering of debt securities will provide the following
terms, where applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the debt securities and whether they are senior, senior subordinated or subordinated debt
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate principal amount of the debt securities being offered and any limit on their aggregate principal
amount, and, if the series is to be issued at a discount from its face amount, the method of computing the accretion of such discount; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price at which the debt securities will be issued, expressed as a percentage of the principal and, if other
than the full principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof or, if applicable, the portion of the principal amount of such debt securities that is convertible
into common stock or preferred stock or the method by which any such portion shall be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if convertible, the terms on which such debt securities are convertible, including the initial conversion price
or rate or the method of calculation, how and when the conversion price or exchange ratio may be adjusted, whether conversion or exchange is mandatory, at the option of the holder or at our option, the conversion or exchange period, and any other
provision in relation thereto, and any applicable limitations on the ownership or transferability of common stock or preferred stock received on conversion; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates, or the method for determining the date or dates, on which the principal of the debt securities
will be payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fixed or variable interest rate or rates of the debt securities, or the method by which the interest rate or
rates is determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates, or the method for determining the date or dates, from which interest will accrue;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which interest will be payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the record dates for interest payment dates, or the method by which we will determine those dates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the persons to whom interest will be payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the basis upon which interest will be calculated if other than that of a
<FONT STYLE="white-space:nowrap">360-day</FONT> year of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any collateral securing the performance of our obligations under the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places where the principal of, premium, if any, and interest on, the debt securities will be
payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where the debt securities may be surrendered for registration of transfer or conversion or exchange;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where notices or demands to or upon us in respect of the debt securities and the applicable indenture may be
served; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions regarding our right to redeem or purchase debt securities or the right of holders to require us to
redeem or purchase debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any right or obligation we have to redeem, repay or purchase the debt securities pursuant to any sinking fund or
analogous provision; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currencies (including any composite currency) in which the debt securities are denominated and
payable if other than United States dollars, and the currency or currencies (including any composite currency) in which principal, premium, if any, and interest, if any, will be payable, and if such payments may be made in a currency other than that
in which the debt securities are denominated, the manner for determining such payments, including the time and manner of determining the exchange rate between the currency in which such securities are denominated and the currency in which such
securities or any of them may be paid, and any additions to, modifications of or deletions from the terms of the debt securities to provide for or to facilitate the issuance of debt securities denominated or payable in a currency other than U.S.
dollars; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the amount of payments of principal of, premium, if any, or interest on, the debt securities may be
determined according to an index, formula or other method and how such amounts will be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be in registered form, bearer form or both, and the terms of these forms;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be issued in whole or in part in the form of a global security and, if
applicable, the identity of the depositary for such global security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provision for electronic issuance of the debt securities or issuance of the debt securities in uncertificated
form; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and upon what terms the debt securities of such series may be defeased or discharged, if different from
the provisions set forth in the indenture for the series to which the supplemental indenture or authorizing resolution relates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions granting special rights to holders of securities upon the occurrence of such events as specified
in the applicable prospectus supplement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any deletions from, modifications of, or additions to our events of default or covenants or other provisions set
forth in the indenture for the series to which the supplemental indenture or authorizing resolution relates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other material terms of the debt securities, which may be different from the terms set forth in this
prospectus. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities at a discount below their principal amount and provide for less
than the entire principal amount thereof to be payable upon declaration of acceleration of the maturity of the debt securities. We refer to any such debt securities throughout this prospectus as &#8220;original issue discount securities.&#8221; The
applicable prospectus supplement will describe the United States federal income tax consequences and other relevant considerations applicable to original issue discount securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the DGCL nor our governing instruments define the term &#8220;substantially all&#8221; as it relates to the sale of assets.
Additionally, Delaware cases interpreting the term &#8220;substantially all&#8221; rely upon the facts and circumstances of each particular case. Consequently, to determine whether a sale of &#8220;substantially all&#8221; of our assets has
occurred, a holder of debt securities must review the financial and other information that we have disclosed to the public. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
applicable prospectus supplement will also describe any material covenants to which a series of debt securities will be subject and the applicability of those covenants to any of our subsidiaries to be restricted thereby, which are referred to
herein as &#8220;restricted subsidiaries.&#8221; The applicable prospectus supplement will also describe provisions for restricted subsidiaries to cease to be restricted by those covenants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Events of Default </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the applicable prospectus supplement states otherwise, when we refer to &#8220;events of default&#8221; as defined in the indentures
with respect to any series of debt securities, we mean: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to pay interest on any debt security of such series when the same becomes due and payable and the
continuance of any such failure for a period of 30 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to pay the principal or premium of any debt security of such series when the same becomes due and
payable at maturity, upon acceleration, redemption or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure or the failure of any restricted subsidiary to comply with any of its agreements or covenants in, or
provisions of, the debt securities of such series or the indenture (as they relate thereto) and such failure continues for a period of 60 days after our receipt of notice of the default from the trustee or from the holders of at least
25&nbsp;percent in aggregate principal amount of the then outstanding debt securities of that series (except in the case of a default with respect to the provisions of the indenture regarding the consolidation, merger, sale, lease, conveyance or
other disposition of all or substantially all of the assets of us (or any other provision specified in the applicable supplemental indenture or authorizing resolution), which will constitute an event of default with notice but without passage of
time); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain events of bankruptcy, insolvency or reorganization occur with respect to Shattuck Labs or any restricted
subsidiary of Shattuck Labs that is a significant subsidiary (as defined in the indenture). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default
occurs and is continuing with respect to debt securities of any series outstanding, then the trustee or the holders of 25% or more in principal amount of the outstanding debt securities of that series will have the right to declare the principal
amount of all the debt securities of that series to be due and payable immediately. However, the holders of at least a majority in principal amount of outstanding debt securities of such series may rescind and annul such declaration and its
consequences, except an acceleration due to nonpayment of principal or interest on such series, if the rescission would not conflict with any judgment or decree and if all existing events of default with respect to such series have been cured or
waived. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture also provides that the holders of at least a majority in principal amount of the outstanding debt securities of any
series, by notice to the trustee, may, on behalf of all holders, waive any existing default and its consequences with respect to such series of debt securities, other than any event of default in payment of principal or interest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture will require the trustee to give notice to the holders of debt securities
within 90 days after the trustee obtains knowledge of a default that has occurred and is continuing. However, the trustee may withhold notice to the holders of any series of debt securities of any default, except a default in payment of principal or
interest, if any, with respect to such series of debt securities, if the trustee considers it in the interest of the holders of such series of debt securities to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority of the outstanding principal amount of the debt securities of any series will have the right to direct the time,
method and place of conducting any proceedings for any remedy available to the trustee with respect to such series, subject to limitations specified in the indenture. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Amendment, Supplement and Waiver </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Without notice to or the consent of any holder, we and the trustee may amend or supplement the indenture or the debt securities of a series:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, omission, defect or inconsistency; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with the provisions of the indenture regarding the consolidation, merger, sale, lease, conveyance or
other disposition of all or substantially all of our assets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide that specific provisions of the indenture shall not apply to a series of debt securities not
previously issued or to make a change to specific provisions of the indenture that only applies to any series of debt securities not previously issued or to additional debt securities of a series not previously issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to create a series and establish its terms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for uncertificated debt securities in addition to or in place of certificated debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to release a guarantor in respect of any series which, in accordance with the terms of the indenture applicable
to such series, ceases to be liable in respect of its guarantee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add a guarantor subsidiary in respect of any series of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to secure any series of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to the covenants of Shattuck Labs for the benefit of the holders or surrender any right or power conferred
upon Shattuck Labs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to appoint a successor trustee with respect to the securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with requirements of the SEC in order to effect or maintain the qualification of the indenture under
the Trust Indenture Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change that does not adversely affect the rights of holders; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to conform the provisions of the indenture to the final offering document in respect of any series of debt
securities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture will provide that we and the trustee may amend or supplement any provision of the debt
securities of a series or of the indenture relating to such series with the written consent of the holders of at least a majority in principal amount of the outstanding debt securities of such series. However, without the consent of each holder of a
debt security the terms of which are directly amended, supplemented or waived, an amendment, supplement or waiver may not: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the amount of debt securities of such series whose holders must consent to an amendment, supplement or
waiver; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the rate of or extend the time for payment of interest, including defaulted interest;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal of or extend the fixed maturity of any debt security or alter the provisions with respect to
redemptions or mandatory offers to repurchase debt securities of a series in a manner adverse to holders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any change that adversely affects any right of a holder to convert or exchange any debt security into or for
shares of our common stock or other securities, cash or other property in accordance with the terms of such security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">modify the ranking or priority of the debt securities of the relevant series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">release any guarantor of any series from any of its obligations under its guarantee or the indenture otherwise
than in accordance with the terms of the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any change to any provision of the indenture relating to the waiver of existing defaults, the rights of
holders to receive payment of principal and interest on the debt securities, or to the provisions regarding amending or supplementing the indenture or the debt securities of a particular series with the written consent of the holders of such series,
except to increase the percentage required for modification or waiver or to provide for consent of each affected holder of debt securities of such series; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a continuing default or event of default in the payment of principal of or interest on the debt securities;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any debt security payable at a place or in money other than that stated in the debt security, or impair the
right of any holder of a debt security to bring suit as permitted by the indenture. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority in
aggregate principal amount of the outstanding debt securities of such series may, on behalf of all holders of debt securities of that series, waive any existing default under, or compliance with, any provision of the debt securities of a particular
series or of the indenture relating to a particular series of debt securities, other than any event of default in payment of interest or principal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Defeasance </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
indenture will permit us to terminate all our respective obligations under the indenture as they relate to any particular series of debt securities, other than the obligation to pay interest, if any, on and the principal of the debt securities of
such series and certain other obligations, at any time by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">depositing in trust with the trustee, under an irrevocable trust agreement, money or government obligations in an
amount sufficient to pay principal of and interest, if any, on the debt securities of such series to their maturity or redemption; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complying with other conditions, including delivery to the trustee of an opinion of counsel to the effect that
holders will not recognize income, gain or loss for federal income tax purposes as a result of our exercise of such right and will be subject to federal income tax on the same amount and in the same manner and at the same times as would have been
the case otherwise. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture will also permit us to terminate all of our respective obligations under the
indenture as they relate to any particular series of debt securities, including the obligations to pay interest, if any, on and the principal of the debt securities of such series and certain other obligations, at any time by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">depositing in trust with the trustee, under an irrevocable trust agreement, money or government obligations in an
amount sufficient to pay principal of and interest, if any, on the debt securities of such series to their maturity or redemption; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complying with other conditions, including delivery to the trustee of an opinion of counsel to the effect that
(A)&nbsp;we have received from, or there has been published by, the Internal Revenue Service a ruling, or (B)&nbsp;since the date such series of debt securities were originally issued, there has been a change in the applicable federal income tax
law, in either case to the effect that, and based thereon such opinion of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
counsel shall state that, holders will not recognize income, gain or loss for federal income tax purposes as a result of our exercise of such right and will be subject to federal income tax on
the same amount and in the same manner and at the same times as would have been the case otherwise. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the
indenture will permit us to terminate substantially all our respective obligations under the indenture as they relate to a particular series of debt securities by depositing with the trustee money or government obligations sufficient to pay all
principal and interest on such series at its maturity or redemption date if the debt securities of such series will become due and payable at maturity within one year or are to be called for redemption within one year of the deposit. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Transfer and Exchange </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder will be able to transfer or exchange debt securities only in accordance with the indenture. The registrar may require a holder, among
other things, to furnish appropriate endorsements and transfer documents, and to pay any taxes and fees required by law or permitted by the indenture. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Concerning the Trustee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture will contain limitations on the rights of the trustee, should it become our creditor, to obtain payment of claims in specified
cases or to realize on property received in respect of any such claim as security or otherwise. The indenture will permit the trustee to engage in other transactions; however, if it acquires any conflicting interest, it must eliminate such conflict
or resign. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture will provide that in case an event of default occurs and is not cured, the trustee will be required, in the
exercise of its power, to use the degree of care of a prudent person in similar circumstances in the conduct of such person&#8217;s own affairs. The trustee shall be under no obligation to exercise any of the rights or powers vested in it by the
indenture at the request or direction of any of the holders pursuant to the indenture, unless such holders shall have offered to the trustee security or indemnity satisfactory to the trustee against the costs, expenses and liabilities which might be
incurred by it in compliance with such request or direction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>No Recourse Against Others </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture will provide that there is no recourse under any obligation, covenant or agreement in the applicable indenture or with respect to
any debt security against any of our or our successor&#8217;s past, present or future stockholders, employees, officers or directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Governing Law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
laws of the State of New York will govern the indenture and the debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series, from time to time. We may
issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from those securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we issue warrants, they will be evidenced by warrant agreements or warrant certificates issued under one or more warrant agreements, which
are contracts between us and an agent for the holders of the warrants. We urge you to read the prospectus supplement related to any series of warrants we may offer, as well as the complete warrant agreement and warrant certificate that contain the
terms of the warrants. If we issue warrants, forms of warrant agreements and warrant certificates relating to warrants for the purchase of common stock, preferred stock and debt securities will be incorporated by reference into the registration
statement of which this prospectus is a part from reports we would subsequently file with the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Units </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue units consisting of any combination of the other types of securities offered under this prospectus in one or more series. We may
evidence each series of units by unit certificates that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or trust company that we select. We will indicate the name and
address of the unit agent in the applicable prospectus supplement relating to a particular series of units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description,
together with the additional information included in any applicable prospectus supplement, summarizes the general features of the units that we may offer under this prospectus. You should read any prospectus supplement and any free writing
prospectus that we may authorize to be provided to you related to the series of units being offered, as well as the complete unit agreements that contain the terms of the units. Specific unit agreements will contain additional important terms and
provisions and we will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from another report that we file with the SEC, the form of each unit agreement relating to units offered
under this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we offer any units, certain terms of that series of units will be described in the applicable prospectus
supplement, including, without limitation, the following, as applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series of units; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identification and description of the separate constituent securities comprising the units;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which the units will be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on and after which the constituent securities comprising the units will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of certain United States federal income tax considerations applicable to the units; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the units and their constituent securities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx122207_9"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination
of these methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also sell equity securities covered by this registration statement in an &#8220;at the market offering&#8221; as defined in Rule
415(a)(4) under the Securities Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price, either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or through the facilities of The Nasdaq Global Select Market or any other securities exchange or quotation or
trading service on which such securities may be listed, quoted or traded at the time of sale; and/or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to or through a market maker otherwise than on The Nasdaq Global Select Market or such other securities exchanges
or quotation or trading services. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such at the market offerings, if any, may be conducted by underwriters acting as
principal or agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided
to you) will describe the terms of the offering of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name or names of any underwriters, dealers or agents, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price of the securities and the proceeds we will receive from the sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any options under which underwriters may purchase additional securities from us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any agency fees or underwriting discounts and other items constituting agents&#8217; or underwriters&#8217;
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any public offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts or concessions allowed or <FONT STYLE="white-space:nowrap">re-allowed</FONT> or paid to dealers;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any securities exchange or market on which the securities may be listed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time
in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable
underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to
purchase all of the securities offered by the prospectus supplement. Any public offering price and any discounts or concessions allowed or <FONT STYLE="white-space:nowrap">re-allowed</FONT> or paid to dealers may change from time to time. We may use
underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell securities directly or through agents we designate from time to time. We will
name any agent involved in the offering and sale of securities, and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis
for the period of its appointment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may authorize agents or underwriters to solicit offers by certain types of institutional investors
to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these
contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may provide agents and
underwriters with indemnification against civil liabilities related to offerings pursuant to this prospectus, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with
respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All securities we offer, other than our shares of common stock, will be new issues of securities with no established trading market. Any
underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with
Regulation M under the Exchange Act. Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a
specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer
when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the
underwriters may discontinue any of the activities at any time. These transactions may be effected on any exchange or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriters who are qualified market makers on The Nasdaq Global Select Market may engage in passive market making transactions in the
securities on The Nasdaq Global Select Market in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply
with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids
are lowered below the passive market maker&#8217;s bid, however, the passive market maker&#8217;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level
above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx122207_10"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain legal matters, including the legality of the securities offered, will be passed upon for us by Gibson, Dunn&nbsp;&amp; Crutcher LLP,
San Francisco, California. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx122207_11"></A>EXPERTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of Shattuck Labs, Inc. as of December&nbsp;31, 2024 and 2023, and for the years then ended, have been incorporated by
reference herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing.
</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx122207_12"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and special reports, proxy statements and other information with the SEC, and we have filed with the SEC a
registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act with respect to the securities offered by this prospectus. This prospectus, which forms part of the registration statement, does not contain all of
the information included in the registration statement, including its exhibits and schedules. For further information about us and the securities described in this prospectus, you should refer to the registration statement, its exhibits and
schedules and our reports, proxies, information statements and other information filed with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our filings are available to the
public on the Internet, through a database maintained by the SEC at <I>www.sec.gov</I>. We also maintain a website at <I>www.shattucklabs.com</I>. We have included our website address for the information of prospective investors and do not intend it
to be an active link to our website. Information contained on our website does not constitute a part of this prospectus or any applicable prospectus supplement (or any document incorporated by reference herein or therein). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx122207_13"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference the information and reports we file with it, which means that we can disclose important
information to you by referring you to these documents. The information incorporated by reference is an important part of this prospectus, and information that we file after the date hereof with the SEC will automatically update and supersede the
information already incorporated by reference. We are incorporating by reference the documents listed below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2024
filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1680367/000168036725000012/sttk-20241231.htm">March&nbsp;
27, 2025</A>, as subsequently amended on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1680367/000168036725000017/sttk-20241231.htm">April&nbsp;
30, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1680367/000168036725000028/sttk-20241231.htm">May&nbsp;
1, 2025</A> (and any portions of our Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1680367/000119312525123592/d47501ddef14a.htm">Schedule 14A</A> filed on May&nbsp;21, 2025 that are
incorporated by reference therein); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31,
2025, June&nbsp;30, 2025 and September&nbsp;30, 2025, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1680367/000168036725000034/sttk-20250331.htm">May&nbsp;
1, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1680367/000168036725000046/sttk-20250630.htm">August&nbsp;
14, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1680367/000168036725000057/sttk-20250930.htm">November&nbsp;6, 2025</A>, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1680367/000119312525159387/d933086d8k.htm">July&nbsp;15,
 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1680367/000119312525173010/d12427d8k.htm">August&nbsp;
5, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1680367/000119312525188078/d95844d8k.htm">August&nbsp;26, 2025</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1680367/000119312520263847/d939403d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> filed with the SEC on October&nbsp;5, 2020, including any amendments or reports filed for the purposes of updating this description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All documents we file with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act shall be deemed incorporated by
reference in this prospectus and to be a part of this prospectus from the date of filing of those documents, with the exception of any portion of any report or document that is not deemed &#8220;filed&#8221; under such provisions on or after the
date of this prospectus, until the earlier of the date on which: (1)&nbsp;all of the securities registered hereunder have been sold; or (2)&nbsp;the registration statement of which this prospectus is a part has been withdrawn. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under no circumstances will any information filed under Items 2.02 or 7.01 of Current Report on
<FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;be</FONT> deemed incorporated herein by reference unless such <FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;expressly</FONT> provides to the contrary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon written or oral request, we will provide without charge to each person to whom a copy of the prospectus is delivered a copy of the
documents incorporated by reference herein (other than exhibits to such documents unless such exhibits are specifically incorporated by reference herein). You may request a copy of these filings, at no cost, by writing, calling or emailing us at the
contact information set forth below. We have not authorized anyone to provide you with any information that differs from that contained in this prospectus. Accordingly, we take no responsibility for any other information that others may give you.
You should not assume that the information in this prospectus is accurate as of any date other than the date of the front cover of this prospectus. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Shattuck Labs, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>500
W. 5th Street, Suite 1200 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Austin, TX 78701 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(512) <FONT STYLE="white-space:nowrap">900-4690</FONT> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:80pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants to Purchase Shares of Common Stock </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g122207g00p38.jpg" ALT="LOGO" STYLE="width:4.07in;height:1.23333in;">
 </P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:70pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Joint Bookrunning Managers </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Leerink Partners</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>J.P.&nbsp;Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Piper&nbsp;Sandler</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>Cantor</B></TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#8195;&#8195;&#8195;&#8195;, 2026 </B></P>
<P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g122207g00p01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g122207g00p01.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1:X4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %IL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M'$<X:H8O6]1<9)V&QZ<IX8 /*%9,7.)]7#@86FW+>)U[5U+Y*:LIJ.,GE%'
MUP;[W E=BS;Q^N*&;BK7T5Q9C'!+$&#VY: 5NFF]ZB0/#-1Z=!#GM EHI<!C
M>TEKNI]ZG/0NTG3&M6 6.Y1NJ<$FEE(9,T XR6Y6XHL5JN[? .F[G=1%X;Q.
MG?-X/..+A!.,^Y5N;O62EH/W+MY_^I_HOWXUDOR7;])_HI[V7:L.M]#V[4#J
M44AJP_,(=Q</"\MZ^Y;4B*&MK^W6W:$N\5JH*1MVKP.*H:R4-;#W-)_*]2C_
M .-9+\EV_2?Z(=ZR4#)TNWZ3_13_ +.-0UNJM(T5XN=JEM514<3O%I#S#<^2
M[V$8*V9?DCVQL<]Y :T9)/8%2';CMBNNL+S66RTU4E)IV%[X6QQGA-2 <%SS
MW'L'<H<X&XQA2'LFVI7G9]=8#%/+4V3BQ/0..6EIZEGY+NU7OT[>*/4%DHKK
M;9/"4E7$V6-W0X(Z'N(Z+((B(B(B*,-O>TIFS[2Y\2>PWVL\BCC<WB Y^4\^
MH#]^%2#4=\N6I+I+<;Y62UE9(22^0],]@'0#U!=6VUM5;*QE7;:F6EJF>;+"
MXM</>KG;N6UF77-!-:;\YOP]2-XO"-:&MGCZ<6/RAV_.IJ1$1$1$7'4SQTU/
M+/.\,AB87O<>@:!DG]RHYMFVQW?6UTK**VU<E+IL.X(X&#A,P&?*>>ISW*)
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MG]\.?]W4_P 0*K+2.$<POW([PF1WA,YZ(B9'>$R.\)D=X5O=S YT1>\?\?\
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MK=%%6P-G;&^-Y+0X9P<+)_%7O_RCM?\ RI/Y)\5>_P#RCM?_ "I/Y)\5>_\
MRCM?_*D_DM+VK;&+ELYL5/=+A=J.LCFG$ CA8YI!()SS]BBM9[0'X=Z;_:5/
M_$:O2)%3G>]U1\*ZUH['"]W@+5$2]N06F5_/(QV@<E JL%N?::-7JFOU'/QL
M@H(S3Q.+1P/>\<QD]H&#R[U;OPT7_F,_S!?AEB((,C"#U&0O/3:[IIVE-H-W
MMA:\0^%,T#GX\N-_,'EV=1[EIRN1NB:I%TT//8IY'.JK7(2SCD!)B<<@-'4
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M.-7;G5M'G#:FB!D:>O4><.G:%'O:1VCJ$1?<$4E1.R&GC?-,\X9'&TN<X]P
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MA-]@KSYT;^%EA_7H/MA>E:(BZ5[N4-HM%9<:H@0TT3I79<&Y '3)7GJ]U9M
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MMHB+L6VL?;[A2UL1<)*:5LS2TX/DD'K[EZ3:9N@O>GK;=!&8A64[)^ G/#Q
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.1$1$1$1$1$1$1$1%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g122207g00p38.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g122207g00p38.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1=>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %T$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         /_A/V9H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ
M<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#8N,"UC,# R(#<Y+C$V
M-#0X."P@,C R,"\P-R\Q,"TR,CHP-CHU,R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N
M8V]M+W!D9B\Q+C,O(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS.F1C/2)H
M='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(*(" @(" @(" @(" @
M>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO
M<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V
M96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B/@H@(" @(" @(" \
M<&1F.E!R;V1U8V5R/D%C<F]B870@1&ES=&EL;&5R(#(P+C @*%=I;F1O=W,I
M/"]P9&8Z4')O9'5C97(^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^4%-C
M<FEP=#4N9&QL(%9E<G-I;VX@-2XR+C(\+WAM<#I#<F5A=&]R5&]O;#X*(" @
M(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C8M,#8M,#=4,#@Z,3<Z-#DK,#4Z
M,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^
M,C R-BTP,2TQ,E0Q-SHT,#HS,BLP-3HS,#PO>&UP.D-R96%T941A=&4^"B @
M(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C8M,#8M,#=4,#@Z,3<Z-#DK
M,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QD8SIT:71L93X*
M(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M>&UL.FQA;F<](G@M9&5F875L="(^36EC<F]S;V9T(%=O<F0@+2!35%1+("T@
M,C R-B!3+3,@4VAE;&8@+2!&;W)M(%,M,R!?1T1#(#$N.2XR-E\U,# T-S<V
M,3$T+C1?+F1O8W@\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@
M(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^.#,R
M,S0S/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @
M/"]D8SIC<F5A=&]R/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\
M+V1C.F9O<FUA=#X*(" @(" @(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^,3PO
M<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E
M240^>&UP+FEI9#HT-V$S.#1B9"TT-C0T+38S-#0M.&4T9"TY,F5C8S,V,6(V
M830\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U;65N
M=$E$/F%D;V)E.F1O8VED.G!H;W1O<VAO<#IB,C8V8V4W.2UA.&9D+34T-&4M
M83)D82TQ83!D,C(X,S4Y-#<\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @
M(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#IC83!C-C=B-RUD
M,6%C+3-F-#(M.6$P9BUF-3,Q-C(U8V$P83 \+WAM<$U-.D]R:6=I;F%L1&]C
M=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F-A,&,V-V(W+60Q86,M,V8T,BTY83!F
M+68U,S$V,C5C83!A,#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.G=H96X^,C R-BTP,2TQ,E0Q-SHU,#HT,"LP-3HS,#PO
M<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E
M06=E;G0^061O8F4@4&AO=&]S:&]P(#(U+C$R("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC
M94E$/GAM<"YI:60Z93DY.3-E9C$M.&%E9"UC.#1E+3@P838M965B8V9A96(S
M9# W/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(V+3 V+3 W5# X.C$W.C0Y*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!0:&]T;W-H;W @,C(N," H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E
M;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T
M.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O
M;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P
M<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A
M;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP
M:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-#=A,S@T8F0M-#8T
M-"TV,S0T+3AE-&0M.3)E8V,S-C%B-F$T/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(V+3 V+3 W5# X.C$W
M.C0Y*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C(N," H5VEN9&]W
M<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO
M>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN
M<W1A;F-E240^>&UP+FEI9#IE.3DY,V5F,2TX865D+6,X-&4M.#!A-BUE96)C
M9F%E8C-D,#<\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E
M9CID;V-U;65N=$E$/GAM<"YD:60Z8V$P8S8W8C<M9#%A8RTS9C0R+3EA,&8M
M9C4S,38R-6-A,&$P/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \
M<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z8V$P8S8W8C<M9#%A
M8RTS9C0R+3EA,&8M9C4S,38R-6-A,&$P/"]S=%)E9CIO<FEG:6YA;$1O8W5M
M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD
M/2)W(C\^_]L 0P &! 4&!00&!@4&!P<&" H0"@H)"0H4#@\,$!<4&!@7%!86
M&ATE'QH;(QP6%B L(",F)RDJ*1D?+3 M*# E*"DH_\  "P@!<@3% 0$1 /_$
M !T  0 " @,! 0             '" 8) P0% 0+_Q !6$  ! P,!! ,*!PT&
M!00 !P   0(#! 4&$0<($B$Q05$3%!@B-V%Q=++1%3)4@9&3L2,S-#5"4E5R
M<Y*4H<$6-E9B@[,7)%/"X2:"HM(E.$-$176$_]H " $!   _ +4@
M :@
M                 &)[2L\M. 8^ZZ7ASGZN1D-/&J<<KEZD3[5ZBG^7[=LV
MR"K>ZFN3[32)*Y\45)XKD:O0CG?E:'D6K:_G=MK654>25M0K/_TZEW&Q?2A9
M?8EMRH\WJH[+>H4H;XK?N:\2=SJ-$Y\/8O3R)L
M                                                    *&;Q.45&
M3;3;@DO&RGMR]Z0Q*[5$X==7:=JZD9@Y[?<*BTUU/<*%ZQU5+(DL;NQR*;(<
M/N+[OBMHN,RM66JI(IG\/1Q.:BKI\YZX
M                                             ->6V*CJ*+:;D4=7
M"^%[ZMTK6N335B]#D\RF&@_+T56*C457+R1$ZS8KLGMOP3LXQVD5TCG-HHW+
MQ]**K454_F98
M                         ""-Y'9%-E\2Y'8-%O5+"C)*?3\)C15Y)_F3
M5=.TIW4P34D[H*N&6GG:NCHY6JUR?,IQ*Y$ZR<=W[8_<<AOE%?+_ $;X+#3N
M[HUDJ*UT[D^+HG9KH7.:U&M1K4T1$T1#Z
M                                               8[E&$X[E$$\=[
MM5/4+,WA=)P\,FGZR<SQ,8V0X5C<LDMNLD+I)-$59U6733LXN@SQK4:U&M1$
M:B:(B=1]
M                 !YF2WRAQNQ5EWNTR0T5*Q9)'KS^9$ZU4IKM(V_9-E%3
M+#8Y'66U:/C:V%=996+UN=U+IV=I%S;]>VJBMOEUU1=4_P";?[R:MDV\+>+3
M<F4>9RNN5NG<C>^EY24_5KYV]O66^HZF&MI(:FED;+!,Q)(WM75'-5-45#F
M     ((V\;<H\0F=8\82"LO3FZS3*O$RE\RZ=+_-U=95>^9KD][KWUMRO]Q?
M.Y-/N<ZQM1.Q$3D>OA&U/+<0K$FH+K45<"NXI*:LD61C_I75/F+C['=IMNVC
M6-9X4;2W2#Q:JC5VKF+^<G:U>TD$
M                                 K'OFY!5PQ62PP5*-HZE'3U$35YN
M5J^+KYNDJX!U%R]T3(:N[X%5V^K\9EKF2&%ZN555KD5=%]!.@     /#SB^L
MQK$[K>)(GRMI('2<#%T5>74:X:JJFK:N>KJI'2SU$CI7O<NJN55UYG$#/]A&
M3/Q;:9::I9)&TM0_O:H8S\MKN2(OH7138 BZHB]H
M                                            !5#?/M"QWJP7>.*3
M@DA?!++^0BHNK4]/-2MX!;S<TM]538=>:JHA<RGJZIKH'KT/1K5153YRP8
M   ,6VHVBIOVS^^VR@1JU-13.;&CET37TFNAJ*U%:O2WQ5]*<CZ#+-D]FEO^
MT6PV^%R-<^H217+U(WQE^PV)-31J)V)H?0
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M:WX;JVHUL7)>]X^S7\Y>OZ";@
M                              <%91TU;"L593Q3Q*BHK9&(Y-%])B,.
MRG!8*MM5%BUK;.UW&CNY="]NG09E!#%!&D<$;(V)T-8U$3Z$/V       8QD
M& 8ID,[)KU8+?5RL31KWQ)JB?,=_'L8LF.TR06.U4E#$BJJ)#&B<U\_2>P
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MS:RRUT]%4M33CB=IJFO0J=G(MIL2V]0Y55PV3*6QTEW?XL,S$TCG73H\RD^
MBK>A\BM^_P!+_<:453H!9#<K_'>3_LHOM4M> #RLL_NM>?4YO8<:U&?%/I+F
MZKY8J'U:;V2\8 .G>:YELM%;73?>Z:%\SN>FJ-15_H:W\FO,N19%<KQ.K^.M
MG=*B.756HJ\D^9#S 2QNQY4W&-IL,53*D=%=8^])/%XE5^NL?HYEYP5YWS/[
MHV?UO_M4J,    #DI_PB']HW[4+@[P7_ .7^B_\ \_V*4Z    !\?\138CLA
M\FF.>J-*2[:_*KDWK;C"3N67\=VSUJ+VD-F,7WIGH0_0 *;;X'E$I/4V_:I!
M)^9/O;O0;#-B?DHQ;U%AFH/'RW);7B=DGNU]JFTU'#TN7FKEZFHG6JE/MJ&W
M[(,K66BL2NL]G=R\3[_)SZ5=^3Z$(9=J]ZOD<Y[UYJYRZK](  1-%XFJK7=K
M5T7Z29-E&WB^8B^*AO;GW6S>*WQ_OL*=K5ZTTZE+B8GD=LRNR4]VL=2VHHYD
M\5R)HJ+UHJ=2H>N#7YMV\KN4>M?]C3 SL6W\947K$?MH;,J/\%A_43[#E *M
M[RFV194J,3Q2I\14X*^KCZ4Y_>V+]JE9$33D@,TV5[/;KM#O[:&W-6*BB5%J
MZM?BPM_JY>I"]N$8I:\-Q^FM%E@2.")J(YZ\W2.ZW.7K53WB-=X7*IL4V:7"
MHHU>VKJ52EAD;^0YW7]"*4+5555<Y=7*NJJO6I\!-&ZME=59=H3+0U>.BNR=
MS>QSU1K')S1R)V]1=<      H7O$914Y+M-N23<;*>WKWI#%QJK4X==7(G4J
MZD: [-MN-3:+A3W&@D='54KTEC<U=%14-C^'W-UYQ6T7)ZL5]52QRNX%Y<2M
M15_F>N     " -[W+)[5B-%8J-9(Y+I*O=9&KI]S;S5OSZH4_1-$T0 LQN;9
M35=]W7%YE62E1O?<+G/7[FO)%:U.Q>DM.      #SLBN]-8;'772ND;'34L2
MR/<[HY?^=#7GM RRNS3*:R\W)R<4KU2*-J^+''KR:GS&.G/04=3<*R*DH()*
MFJF=PQQ1MU<Y>Q$)_P 1W8KM<*9)LBNC+:CXVO;%"Q)'M5>E':\DT\QF5'NN
M6..F5M3>ZZ:9>AZ,:W3YCQ[CNK,923NMV22R5*)K$R:!$:J]BJG,@K/=G^0X
M/6+#?:&2.!SU9%5-36*73K1?>8H?6/=&]KXW.8]JZM<U=%1>U"\V[GM!_MMA
MZ4]8[_\ %;8UD$ZN=JLJ:<G_ #Z<R6"*MZ'R*W[_ $O]QI15.@%D-RO\=Y-^
MRB_J6O !Y66?W6O/J<WL.-:C/BGTES=6\L5#ZK-[)>, $);V65)9-GGP5%W-
MU1>']P5%?HYK$YJY$Z^I/G*6HFB: '[@GFIIXJBED='/"])&/:NBM<BZHJ&Q
MO9[D$64X;:KQ DB-J86JO=/C<2<EU^=#(2)MXC KMGM@M])9%A[K!/W1W=%T
MY:*A G@W9IVT7U@\&[-.VB^L'@W9IVT7UAT[SN_Y;:+167&J6C[A2Q.E?I)J
MNB)JNA$"+R!D&!XI7YID<5EM*QI5R,=(BR+HW1J:J27X-V:=M%]8/!NS3MHO
MK!X-V:=M%]8?J+=PS-DL;E6BT:]%7[IV*6!VKX1=,GV54V/VY8N_H^Y:\:Z-
M\5.97SP;LT[:+ZP>#=FG;1?6#P;LT[:+ZP_,F[CF<<;WN6BT:BJOW3L(:GB=
M!/)$_P"-&Y6KIVHNAQGK8G8JK)LCH++;U8E76/[G&KUT3715Y_02LN[;FB*O
M.B^L/G@W9IVT7U@\&[-.VB^L/CMVW-%:J:T7UA;; +546/#;1;*WA6HI8$C?
MP]&J%%=M?E6R;UMQA)V[-^.[9ZU%[2&S*+[TST(?H %-M\#RB4GJ;?M4@D_,
MGWMWH-AFQ/R48MZBPS4\S);W18Y8JV[7.5(Z6EB61ZKUZ=2>=2AFUK:1<]HM
M^=4U3GP6N)?^5HN+5L:?G+VN7M,&!E6%[/\ ),PG8VR6NHE@5R(ZH5O#&Q%7
MIU7I3T$QV#=<NDTLJ7V]P4T:)XBTS.-7+Y]3FO\ NM5L,$;K#?F5,JKH]M5'
MP(B=J*A%6>;)LKPR5[JZW25-$FB)5TS>.-55-=.U/G0P$$B;$MHU5@&41223
M/6RU+D95P*J\*(J_'1.U"^U)4PUE+%4TTB202L1['IT.:J:HIRFOS;MY7LH]
M:3V&F!G8MOXRHO6(_;0V94?X)#^HGV'*"N6\;MG^"FS8QB=2UUQ=XM951NU[
M@BI\1%3\K["IO-55555<JZJJKJJKV@S/9=L]NNT*_)0VYKH:2/QJFK5NK(FZ
M_P U[$+W85BEJPVPPVJR4[8:=G-SM/&D=UN<O6JGO A+>YAEEV6HZ.-SVQUD
M3GJU->%.?-?,4M ,]V#T:UVUG'8DD6/2=)-4_P O/0V!      &O/;)15-!M
M.R*.LA=$]]4Z5J.3I8[H5/,IA@/S)KP+PIJO4B=9L6V46U+5LYQVD:K]6T4;
MEX^E%<U%7[3*P     5<WU(I.Z8Q+P.[DBRM5^G)%5$T37M*Q@$X[G]-W7:9
M5S<:M[A1.71/RM51.?TES@      0OO9W.JM^RJ:&E?P,K*B."7ETL5=53^2
M%*$Z 6MW/\*HVV.HRVMIXI:V:9T-)(O-8HT31W+H157K+) 'B9GCE#E6-UUI
MN4$<L51&YK>)->!VBZ.3L5%-=N26>HQZ_P!PM%;IWS13.A?HNJ:H>:2UNOW^
M2S;4Z2E9'W2.YM[V=STX>M%\Y>4BK>A\BM^_TO\ <:453H!9#<K_ !WDW[*+
M^I:\ 'E99_=:\^IS>PXUJ,^*?27-U7RQ4/JLWLEXP 48WFLK3)]I4]/!*DM'
M:$6EBT;IH_7Q_3S0B<R' \2N.;9%%9K1P-J)&/?QR:\#4:FO-4Z->@\2LII*
M.LJ*6=$2:"1T3T3J<U51?L.$M;N;91W>S77&ZF1[I::7OB'C?JG Y-%:U/,J
M?S+)  &,;3_)YD7J4OLJ:YF_%3T'TES=4\LM#ZK/[)>,   '!7_@-1^S=]AK
M1NOXTK/VS_:4ZIGVP+RR8KZROL.-@( !KUVU^5;)O6W&%';LOX[MGK47M(;,
MHOO3/0A^@ 4VWP/*)2>IM^U2"3\R?>W>@V&;$_)1BWJ+#-2I>]QG<M9>8<3H
M9)&4U*G=*Q$71)'K\5%[41"N@)NW<]D<>;3R7O(&O2R4TB-CAT5.^7>G\U"X
M]KMU':J&&BMM-%34D+>&.*)O"UJ>9#M _,D;)8W,D:U[')HK7)JBH5 WE=DM
M-C$G]H\=B2*V3O1L],U%5(7JJ^,G8U?Y$ A4U312YFZ;F$E\PJ>T5\Z25ELD
MX(T<_5[HE1%1?0BZH3F:_-NWE>RCUI/8:8&=BV_C*B]8C]M#9E1_@L/ZB?8<
MI7C>'VV)8VSXUB,Z.NSD5E75L5%2F1>7"W_/]A4A[G/>Y\CG/D>JN<YRZJY5
MZ55>T^&8[+L N>T#(&4%N:L=-&J.J:ER+PQ,U^WL0O=@V)6K"[!!:;+ V.&-
M-7OT\:5W6YR]:F0 'DY78J3)<=K[/<6JZEK(EC>B+IZ%^G0U];0,-NV#W^>V
MWFG=&G&O<)NEDS->3FK_ $,;/K45SVL:BN>Y=&M3FJKV(6_W8]E-5C%/)D>0
MQ-9<*R)J4].Y$58&=/$O8Y?L)_ !T;U=[?9*!];=JN&DI6=,DKM$]!#&1;S&
M)6^ICCM4%9=&*B\<D3.!K5[/&5-3Q&[T]J[N[BL%;W'J5'-XOM,EQ3>.P^\2
MK%<EJ;3*KT8Q)V:M=KUZMUT)CM]=37&CCJJ">.HII$U9)&[5KD\RG8 !!6\=
ML@DS&%<BQ]%=?J:)(W4ZNT;41HJ\D[')JNG:4ZJZ>:BJI*6LB?!4QKPOBD31
MS5\Z'"KD;TJB$Z;ONQVX9!?*2^Y%1.AL-.[NC&2+PNJ'I\71.GAUT7SERVM1
MK4:U-$1-$0^@ CC-]L^'8E)+3U=R2IKV,5R4],U7JJZZ::IR1?2I'$F]/9^#
M[E8*]7?YG-1/M.>BWI,?EJ(F5-GN$$;E1'R>*Y&IV])+^%Y]C>9PJ_'KG%4N
M1518UU:]-.OA7GH90 #"ML&$19]A-7:%5K:I%2:E>Y51&RMUX=?-ST*"7ZS7
M''KK-;+W2R4E="NCXWIT^=.U/.= YZ"DJ+A6PT=! ^HJYW(R.*--7.52\F[]
MLS=L]QF5;DL<EYKG)+4*U$7N2:<HT7L3K\Y*@      (*WP_)G3]O?T7]2FH
M+=;G>4P56(UF-S/C964$[I8F?E/B=HO%\RZH6% !67:1N\WS)LXN]ZH+G;X:
M>MF[JUDG%Q)RZ]$,:\%S)OTS:_\ Y^XR;9GN^7[%<ZM%[K+I;Y8*.7NCF1\7
M$Y-.A-4+,D5;T/D5OW^E_N-**IT LAN5_CO)OV47]2UX /*RS^ZUY]3F]AQK
M49\4^DN;JOEBH?5IO9+Q@'@9]?X<7PZ[7FH>YC*2!7HYK>)>)>3>7I5#7+6U
M<U?755;5O62IJ9732OZ.)SEU53A+2;F>-HE)><CE25LCWI21:IXCF(B*JI\_
M(B?>*QAV-;3KCPQ,BI+@JU=.UBZ\E7QM?GU(S,VV*Y)_93:79KDYT;8'2+3S
M+)R:C'\E7YC8/&]LD;7L5'-<B*BIUHI^@ 8QM/\ )YD7J4OLJ:YF_%3T'TES
M=4\LM!ZK/[)>,   '!7_ (#4?LW?8:T;K^-*S]L_VE.J9]L"\LF*^LK[#C8"
M  :]MM?E6R;UMQA)W++^.[9ZU%[2&S&+[TST(?H %-M\#RB4GJ;?M4@D_+_O
M;O0;#-B?DHQ;U%AE5WK/@^UUE8K>/O>)TO#VZ(JZ&MW)+K+?,AN5TJ%=W2KJ
M'S*CG:\**Y51/F/-/;PC')\MRRV6*E1W'62HURM5$5K$YN=S[$0V+6*V4]FL
MU%;:-B,IZ6%L+$1$3DB::\CO  \'/++%D.'W>U3Q+,RI@<U&(NBJY.;>?I1#
M7)6TTE'6U%-.W@EAD=&]J]2HNBH<)-FZ1>&6_::^@>W5;C3.8U>Q6IQ?T+IF
MOS;MY7LH]:_[&F!G8MWXRHO6(_;0V94?X)#^HGV%?MXC;6VQ1U&-8G.UUV>W
MAJ:IJ:I3(O2U/\_V%1W.<][GO<KGN57.<Y=5<J]*JI\,JV;X1<\\R.*UVMBM
M9\:HJ%^+"SM7S]B%\L!P^V83CM/:;1$C6,:G=)5^-*[K<Y3(P #RLCQZU9);
MI*&]T,%93O:K=)&(JMU[%Z47T$0WW=HQ&XURST5376V)41.X0*U6IY^::F98
M7L@Q#$Y(:BAMD<];&WA[YJ$1[E7MTZ$4D$ &(;3<^M6 8^^XW21KIG>+3TR.
M\>9_8GF[5**9YF][S>[S5U[JWN8Y?N=,UR]RB;U(C?ZF- =1G&S':7?<!N<,
ME!423VWC19J%[EX'MZ].Q2\V"9=:\UQZGNUFG:^*1-'QZ^-$[K:Y.I3(0 8Y
MD^$8YD\,D=[M%)4J]45TBQHCU_\ <G,\K'ME&%6"H?/;[!2)*YO"JRM[IR\W
M%J9NQK6,1K&HUJ)HB(FB(A] /S+(R&)\DKD9&Q%<YRKHB(G2I3_;AMVN%[K*
MVQ8I*M):8W+&^LB<J25'4NB]32 NE5<JJKE7557FJJ =FVU]7:ZR.KMM3+2U
M4:ZMEB<K53Z"XN[_ +9TS-/@3(>XT]ZAC;W.3BT2J3K5$_.\Q.( ,>R_"\?R
MZF2#(+93U:-5%1[FZ/33J1R<]/,1/6;L6*3W*2HAN%R@@<_C2G8K5:U-?BHJ
MIKH29ANSG%\/<Y]CM,$,[M-9G-XG_,J]'S&6@      &&;8L6_M?L]N]JCC8
MZJ='QTZN;KPR-75%3S]*?.:]ZB"2FJ):>H8Z.:)RL>UR:*U47145#C.]9+O<
M+%<HKA9ZR6CK8OB2Q.T5/>A8G"MY^:&GAILKM*3/1S&=]4S]/%Z%<YJZZKU\
MB7K!MOP6]5BTT%YC@?P\6M0BQM^E>1FMHR.S7E'K:KK15B,^-W&9KM/3HIZC
M7-<FK514[44^@ BK>A\BM^_TO]QI15.@%C-S&>*"\Y,LTK(T[E%\=R)UJ6I^
M$:+Y93_6)[Q\(T7RRG^L3WCX1HOEE/\ 6)[Q\(T7RRG^L3WGEY37T;\8O"-J
MZ=5[SFY)(GYBFMUGQ3Z2YNJ^6*A]6F]DO& 5OWQLJ[ULUMQF!ST?6N[XF5K]
M$X&K\5R>=?L*H!&N>J-B:KI'+HUJ)JJJO0B&PW8_C3,3V>VBV-[MQ)$DLB2I
MHYKW^,Y-/,JD4;X^-+68S;+_ $\4?'02K'/)^4L;NA/1J5)/BIJFAL"V&92S
M*]G%IJG3-EK((FT]3HFG#(U-%3[#/@ 8QM/\GF1>I2^RIKF;\5/0?27-U3RR
MT'JL_LEXP   <%?^ U'[-WV&M&Z_C2M_;/\ :4ZIGVP+RR8KZROL.-@( !KU
MVU^5;)O6W&%';LOX[MGK47M(;,HOO3/0A^@ 4VWP?*)2>IM^U2"3\R?>W>@V
M&;$_)1BWJ+#RMXZJ=2;'<A?'.Z&1T;&-<UVBKJ].2?-J4*3H!/>YW9HJW.;E
M<YZ=7K0T^D,O4QSN2_/H7$  !'%PV*8)7UU1655CC?/42.ED=QKS<JZJOTJ<
M'_ G9]^@8_WW'J8SLGP[&;S!=;-:&4]="BI'(CE735-%_DIG1K\V[^5W*/6D
M]AI@9V+;SN=$B=/?$?MH6SV_;9DQJ@3',7G8Z]OC:E1.U=4IFJG5I^6O\BHK
MWND>Y\CW/D>JN<YRZJY5Z553X91L[PB[9W?X[99XG</QIZA6^)"SM5>WS%[=
MG.#6G \?CMEHC37XTT[D3CF?UJJ_T,J     !^97MBB?(]=&L17*OF0H%MQS
M63-L]KJN-[EMU,Y8*1BIIHU.2KIVJNI'X Z@3%NRYY)BV:LM=7,J6FYKW-S%
MZ&R_DN3T]!=T    $#[UF>26#&8;%;9W1UUSXDE=&]$='$G3JG3XVNA3A.0
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M^@ #DI:J6BJ8:JF=P3P/21CNQR+JBFRVQ3R55DM]1,NLLM/'(]>U5:BJ=X
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M2=DBJWK:B^,GGU34V.6&Z07JS45SI.+O>JB;*SB31=%37FA'&]#Y%;]Z8O\
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MERBTYM7Y]5*T  !>2%Z=VG$WXQLTHW54<D5=<'+53,>OQ=>3>75R1"5@
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M\>RYK62.8CZV)KD1=.).?)2EP!)N[;-)'M@LC8Y7L:]7-<C7:(Y.'H7M+Y
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MSIZR-/'B7L\[?,4LVD[-<@V?W!T-WIUGHEYQU\#%6)R:\M5_)7S*86G--4
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M%'31Q\$2_K:\U+"QL;'&UD;6L8U-&M:FB(G8B'Z
M                                           ..I@CJ:>2"=C9(I&J
MQ[7)JBHO2A1C;SLNK<#ODU=3QI)C]7+_ ,O*Q%^Y*OY#NSS+UD5@ ][!\3NF
M:9#3V>RPJ^61R=TE5%X(&:\WN7J0OYLYQ&DPC$:&QT+NZ-IV^/*J:+*]5U5R
MF2@
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MLHW(B:4S5C>SGS7IY\M>1:C%,DM>5V6&ZV.J;4T<O0Y.2M7K:J=2H>N
M
M5^WN\QJ;1C-)CM&CXW7;5TL[7::1L7FWYRH*)HFB=" ?.J+VH7FW:LTDR[ (
MXJQSGUUK5M+*]4^,FGBK]"$L@ !414T5$5#XUC6)HUJ-3S)H?0 #S\@NM-8[
M+6W.ND;'3TL3I7N=T)HAKERK(*_*<@K+Q=IEFJJAZKJO0UGY+4[$1#R@3#NP
MYE4X[M IK5)4\%IN:K'+'(_1C9-/%<GGY:?.7>
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M/H,BV=4%3<\ZL5)1,5\[ZMBHB=B+JJ_0AL<8FC&HO3H?0
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M6T,3^6NJ:*]4^E"T
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M&H9;TK:J--.Z57CHJ]O#T:DG-1&HB-1$1.A$
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M]XBR9+6TUKOE.^U7"5$:DKW(L+WZ]"+U?.3FBZIJG0
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MM J\GQRKLU[JF37"VN:V%5^^/@TY*O;HO+4G4
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M[L8Q+"*GONWTLE57IIPU%6Y'N8O^5-.1)
M                                  !QU,\-+3R3U,K(H8VJY\CW<+6H
MG6JJ5?VF;RT[*ZIM^#4L+HH7\/PC.O$V31>? SL\ZD=MW@=H+:IT_P (TJ\2
M:=S6!.!/0A+.RC>/ANE92VG-*>*CJ)5X&U\;M(E7_,GY/86-C>V2-KXW(YCD
M16N:NJ*G:A^@#Q\KQJTY5:);9?J**KI'\^%Z:JU>IS5ZE\Y4[:5NYWZR335>
M)*MXM^NK:?32=FJ]"=3D3M(<N&/WFVUDM)7VBO@J8EX7QN@=JB_,AUO@VO\
MT?6_P[_<2'A6Q#-,FJ6)+;9+31.1KEJ:Q--6KUM3I5=.HMELGV5V39S0R)0(
MM5<IT1)ZV5J<;].I/S6^8D  $?;7-J5HV=6M'U2MJ[K*FM/0,?H]_/XR]C?.
M5INF\EF]37S34*4%'3.75D"Q]TX$[.)>D[V,;S&54-<KK_1TERI7(B*R-.Y.
M9SYJB\]>746JPC+K1F=DCN=BJFSP+R>W\J-WYKDZE/?
M                                                *[[X>5U5NQ^W
MXY2\3([HJR32M?HJL8OQ-.Q?Z%2$31-$Z %1%147H+N[KN839/L_2DK.-U3:
M'-I5D=^6W3Q?H1-"8@ #\.BC<NKF-5>U4/G<(O\ I,_=.0  ZEWN$%KM=575
M<C8X*>-TCWN71$1$-<>7Y%797D=;>;K,Z:HG>O"KEU1C$5>%J=B(AXX)2W=,
MTJ,4V@T5-)5.CM%Q?W&ICZ6JY4\5WIUTYE[475$5
M                                             "HV^?1NBRRP5BRN
M<V:E>Q(UZ&\+NE/3J5Y +:;EC')B^1N5KD:ZKCX55.2^*O06+     !B>UBV
M5=XV=7^@MT7=:J>E<V-FNG$OI-=;45J<*\E;XJIYT/H/>P"CJ*_-K)34<3II
MW5<:HQO2J(NJ_P C9 Q-&-1>P^@
M                               C_;9L]9M"P^6@A?%!<XG)+2SO8BZ.
M3\E5Z41>A2AU\M-?8KK4VV\4LM)6T[U8^.1NG1UIVHO:=$]C$L:NN67J"UV*
MDDJ*B5W"KFM561IUN<O0B(; =F^)T^%X?;K-3<*N@C3NTB)IW21>;G?29,
M   #X]J/8YKDU:Y-%3M0HUM[V55>#Y#/6VJDGFQRI^ZMF:Q7-IW*O-CM.A.Q
M2)DT7H'7ITJO)$0LYNK;+ZJ*O_M?D%)-2K#JRAAF:K'*JIHLFG9HJHA:,
M
M  &,YE@F-YE V+(K5!5\*HK9.;7II_F31=/,8?X/NSG77X"7^(D]YG>*8G9,
M3H$H\?MT%'#U\">,[TN7FI[8      .*KIH*RFDIZN&.:"1.%\<C4<UR=BHO
M215?MWW ;HLTD5K?13RO619*>9R:*O2B)KHB'I8SL2P3'JN"KH[(R2KA3Q9)
MWNDY]NBKIK\Q)")HFB=
M                             !T[S=*&RVZ:ONM3'2T<*<4DLBZ(B%:\
MUWH%9+)!A]J9(UDJHE36:\,C$ZT:FBIKYSQ;%O1WZ.O1U\LU#-1\*ZMIE<Q^
MO5S550L/LYVD8_GM$LEEJO\ FHVHLU+(G#)&NG/EUIYT,S
M
M*8;TF?U-_P NEQZAJG? UOT;)&W5$DGYZ\7;IRT(/![N#915X;E-#?*!5XZ9
M^KV(NB2,7DYJ_,;%;'<&7:S4-PB:K8ZJ!D[6KTHCFHNG\SN@
M
M UU;5O*3DVGRZ3[3%0?F73N;M>C0V);((:R#9ICC+C*V6H[RC7B3\U4U:GT:
M&7@
M                JCO5;,JYEWES&S4Z2V]T36UT<3?&B<BK]TTZT75-5ZBM
MR+JG+H!FVR'!*K/LOI;>R.5MM:[CJZAK=48Q.>GI7H^<V V^DAM]!34=*W@@
MIXVQ1M[&M31/L.P
M                            #\311SPOBF8V2)Z<+F.35')V*A"N;;N>
M+7V2>HL[Y+-52.XON+>*).W1G4>%8-URSTM6Y]ZO=57P<.C8HXTBY]NJ*I.F
M,XY:<9ML=!8Z&"CIVIT1L1%<O:J]:GK
M
J                                                     __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g122207g41w67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g122207g41w67.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[1<H4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %PL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M             /_A04QH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_
M>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK
M8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z
M>&UP=&L](D%D;V)E(%A-4"!#;W)E(#DN,2UC,# R(#<Y+F$V838S.38L(#(P
M,C0O,#,O,3(M,#<Z-#@Z,C,@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS
M.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X
M+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O
M,2XS+R(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B @(" @(" @(" @('AM;&YS.G!H
M;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(*
M(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @
M(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN<SIT
M:69F/2)H='1P.B\O;G,N861O8F4N8V]M+W1I9F8O,2XP+R(*(" @(" @(" @
M(" @>&UL;G,Z97AI9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]E>&EF+S$N,"\B
M/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%C<F]B870@1&ES=&EL;&5R(#(P
M+C @*%=I;F1O=W,I/"]P9&8Z4')O9'5C97(^"B @(" @(" @(#QX;7 Z0W)E
M871O<E1O;VP^4%-C<FEP=#4N9&QL(%9E<G-I;VX@-2XR+C(\+WAM<#I#<F5A
M=&]R5&]O;#X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C8M,#$M,3)4
M,3<Z-3 Z-3$K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP
M.D-R96%T941A=&4^,C R-BTP,2TQ,E0Q-SHT,#HS,BLP-3HS,#PO>&UP.D-R
M96%T941A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C8M,#$M
M,3)4,3<Z-3 Z-3$K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @
M(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^36EC<F]S;V9T(%=O
M<F0@+2!35%1+("T@,C R-B!3+3,@4VAE;&8@+2!&;W)M(%,M,R!?1T1#(#$N
M.2XR-E\U,# T-S<V,3$T+C1?+F1O8W@\+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z
M8W)E871O<CX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D^.#,R,S0S/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E
M<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @(" \9&,Z9F]R;6%T
M/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @(" @/'!H;W1O<VAO<#I#
M;VQO<DUO9&4^,3PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @(" @/'AM
M<$U-.DEN<W1A;F-E240^>&UP+FEI9#IA-C,X-F)A9BTQ,V(T+6,U-&8M.#1C
M,BUD8C9E9C5A.#,T8V4\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX
M;7!-33I$;V-U;65N=$E$/F%D;V)E.F1O8VED.G!H;W1O<VAO<#HW-C9C86-A
M,"TU,3@P+39D-#4M.30S92UC-#8T-F%F,F4R,#D\+WAM<$U-.D1O8W5M96YT
M240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I
M9#IC83!C-C=B-RUD,6%C+3-F-#(M.6$P9BUF-3,Q-C(U8V$P83 \+WAM<$U-
M.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^
M"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F-A,&,V-V(W+60Q
M86,M,V8T,BTY83!F+68U,S$V,C5C83!A,#PO<W1%=G0Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R-BTP,2TQ,E0Q-SHU
M,#HT,"LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(U+C$R("A7:6YD
M;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,S!C,S0S.3$M.35E-BTV-31D+3DR
M93DM,&)E-6,R-V(R-3!D/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(V+3 Q+3$R5#$W.C4P.C4Q*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C4N,3(@*%=I;F1O=W,I/"]S=$5V
M=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA
M;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R
M=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP
M87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO
M<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO
M;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A
M<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED
M.F$V,S@V8F%F+3$S8C0M8S4T9BTX-&,R+61B-F5F-6$X,S1C93PO<W1%=G0Z
M:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R
M-BTP,2TQ,E0Q-SHU,#HU,2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P
M(#(U+C$R("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E
M<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ
M1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C,P8S,T,SDQ+3DU938M
M-C4T9"TY,F4Y+3!B935C,C=B,C4P9#PO<W12968Z:6YS=&%N8V5)1#X*(" @
M(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#IC83!C-C=B-RUD
M,6%C+3-F-#(M.6$P9BUF-3,Q-C(U8V$P83 \+W-T4F5F.F1O8W5M96YT240^
M"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I
M9#IC83!C-C=B-RUD,6%C+3-F-#(M.6$P9BUF-3,Q-C(U8V$P83 \+W-T4F5F
M.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D
M1G)O;3X*(" @(" @(" @/'1I9F8Z3W)I96YT871I;VX^,3PO=&EF9CI/<FEE
M;G1A=&EO;CX*(" @(" @(" @/'1I9F8Z6%)E<V]L=71I;VX^,S P+S$\+W1I
M9F8Z6%)E<V]L=71I;VX^"B @(" @(" @(#QT:69F.EE297-O;'5T:6]N/C,P
M,"\Q/"]T:69F.EE297-O;'5T:6]N/@H@(" @(" @(" \=&EF9CI297-O;'5T
M:6]N56YI=#XR/"]T:69F.E)E<V]L=71I;VY5;FET/@H@(" @(" @(" \97AI
M9CI#;VQO<E-P86-E/C8U-3,U/"]E>&EF.D-O;&]R4W!A8V4^"B @(" @(" @
M(#QE>&EF.E!I>&5L6$1I;65N<VEO;CXQ,C4W/"]E>&EF.E!I>&5L6$1I;65N
M<VEO;CX*(" @(" @(" @/&5X:68Z4&EX96Q91&EM96YS:6]N/C,X,3PO97AI
M9CI0:7AE;%E$:6UE;G-I;VX^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P &! 4&!00&
M!@4&!P<&" H0"@H)"0H4#@\,$!<4&!@7%!86&ATE'QH;(QP6%B L(",F)RDJ
M*1D?+3 M*# E*"DH_\  "P@!?03I 0$1 /_$ !T  0 " @,! 0
M   '" 8) P0% 0+_Q !5$  ! P("!00*#0H$!@(# 0   0(#! 4&$0<($B$Q
M$T%1810B-W%S@9&QLM$5%A@C,C0U0E)5=).4-E-45F)R=9*AP3.$L\(7)$."
MHN%CTB6#\$3_V@ ( 0$  #\ M2
M                                                      09IET]
M4F$:I]IPY%%<+M&[9F<]WO<"IS+EQ4KQ7Z:L>559-.S$-5 V1VTD462-9U)N
M,JP'K%XEL<C8L0-]FJ17JY[GNV9D3+@U>'E0MA@;%UJQG88+K9:ALD3T3E(\
M^VB=SM<G,ID
M                           !@6G'%<N#]&]TN5(Y[*MR)! ]B)FQ[UR1
MV_H* U$TM342SU$CI)I7*][W+FKG*N:JIQ@FG54Q366?2&RS1JCJ*[)LR,<O
MP7-151R=?,76
M                            (<UL&/?HAJ]AKG;-5 JY)P3;XE(T ,[T
M%T<E?I8PY#%*L3DJ.4VDXY-WJAL$
M                                            /*Q39*;$>'J^T5NZ
M"LB6)RY9JW/G3K0H#I)P+=<!8@EMUUA=R*N5::I1O:3LZ47IZ4,3/U&UTCVL
MC:Y[W+DUK4S55Z$0MKJL:,JBQT\^)K_2NBKJEB,I8)H\G1,XJ_?O15X=XL0
M
M               #R,38;M&)[<ZBOM!#64[FN1$D;O;FF2JU>*+UH0[?M63"
MM;5I):JNLML.62PL7E$SZ<W;S,<%:%\&X3JH*RCMO+W")N25%0Y7KG])$7<B
MDD
M               A[2]ISL^"'S6VV-;<[ZU-\**O)PK^VY/,A7RYZP>/:RNE
MGIZZFHHGKVL$<".:Q.C-=ZF0X)UEL0V^>"#$U-37&D67.6H8U62M8O,U$W+D
M6KPGB6U8KLT5TL54VII)/G(F2M7H5.93V       0SIBTZ6W!%2^UVB*.YWI
MF?*1JY4CA7H>J<_4A7VNU@<?U-9--#<:>FC>[-L+*=JM8G0BKO,NP!K+W>AE
M93XPI8JZES<KJF!NS*G0FSP5"U&'+Y;\16>FNEGJ65-'4,1['M\RIS+U'I
M
M     &)Z5L328/P!>;W!%RLU-%[VW/+MG*C47Q9YFO.NJYZ^NJ:RKD62IJ)'
M2R/7BYRKFJG "9]5[&]1A[',-FFEE=;KLY(>23>C9?FNZN?,NP      8'IN
MQ:F#M'ETKX:AL->]B0TN?%TCERW=>6:^(H!43RU51+45,CY9Y7*^1[US<YR\
M55><XP3UJEXREM6+9K!53HE#<418VR/7)LJ<$:G#-<_Z(7%
M                                                      (DUI:>
MHFT0762";DXX7QOE;]-NTB9>54*-H 9EH8[JV%?M\9L-      ((UPHI)-'-
M(YC'.:RM8KE1,]E,EWJ4W ,XT(4<]9I5PTE,Q7K'6QRORYFHN:J;!P
M
M#R\3V2DQ'8*ZT7!B.IJN-8W;L\NA>^BY*:^-(&$+C@K$E7:KG#(UC)')!,Y-
MTT>>YR>(QL9Y<5+0:JVC&LIZKVW7RGY&)T>5!%(U,W(O&3JX)EWU+/@
M'AXYP]!BK"=SLE4JI%61*S-%R5%1<T7RHAKVQAAJYX2OU3:;U3.@J8G*C<][
M9&\SFKSHIXH7<6LU3]'-3;V38LO-/)!+.Q&4+7+EG&J=LY4Z]V7>4LF
M
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MW_:<YW;-XJJG)KI.<VUX;V7.;[_)P7+YI5;E)/SDG\RCE)/SDG\REO-3-57
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MV.6"XPWBR4%QIG*Z&J@9,Q5XJCDS_N=\ $)ZW7<J_P [#YU*6 LAJ6_+>(_
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M<W:.-:NTKE5SE5555557G   +1:EU7,Z'$-(KEY!CF2(WF15W+YBSH
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MIY&N=#=$[$7M\D8JKFCEZ>&7C+R@ A/6Z[E7^=A\ZE+ 60U+?EO$?@8_.6O
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M5S1R+P5#D     !\<F;51.@USZ3+=4VK2!?Z2NC6.=M6]ZM_9<N:+XT4QD
M%L-3.SSP6.]W9ZIV/4S-A8G/FQ,U])"QX   !UKG2,KK;5TDBJC*B%\3E3BB
M.147SFMW%%L2RXDNEL:KW-I*A\37/3)51%W*>6  "X6IY9V4V!J^Y/B>RHJ:
MM69N;DCF-:W)4\:J3Z          #\\HSZ;?*.49]-OE/K7-<O:N1>\I] .&
MII:>JA=%50131.XLD8CFKXE(ITGZ#<.XLHJB:U4T%JO"IFR>%F3'*G,YJ;LN
M\4KOUIJK%>:VUW%G)U=)*Z*1O0J*= [-LK:BW7&FK**5T-3!(V2.1O%KD7<I
MLGP_.^JL5MJ)7[<DM-&]SNE5:BJI%FMEW'JS[5!Z12($_:F/Y?7S^')_J(7!
M  7@IKLTL]TO$WVZ7TC$SL6_X_3>%;YT-EUK^3:7P3?,=DA36MQ8MAP"ELIY
MG1U=V<L*(B<8T^&B^)2E: ]S"N++YA.HJ)\.W*:@EJ&HR5T67;(BYHBYH9'_
M ,9-('ZT5WD;ZA_QDT@?K17>1OJ'_&32!^M%=Y&^HPNZW&JNUQGKKA,LU7.[
M:DD5$17+T[CJ'/05+Z*NIZJ)522"1LC<ERWHN?$V,:/\01XHP?:KQ$L>=3"U
MSVL=M(QW.W/I13( "$];KN5?YV'SJ4L!9#4M^6\1^!C\Y:\    UTZ5.Z3B?
M^(S^FIBQS4?QN#]]OG-EUH^2J+P#/10[8 *U:Z:?_B<-K_\ /)Z)54%O=3%4
M7 UY1%WI7[_Y$+!  ZEW^2JWP+_14UH57QJ;]]?.<1E^B#NG8:^VQ^D;$"N.
MN=9JFIL%BNT6SV-13/CEZ<WY(WS%3@6EU+KXQ:3$%B=&J2,>RK23:XHO:Y9>
M(LT  ?'+DU57F3,JCBW6/Q+:<3W6WT=NM4E/35#XHWKMJKFHN2+N4\GW3^+/
MJNT^1_K,BT=ZPF),28WLMFK+=;8Z>MJ60O='M[2(J\4S4M&4GUM>ZT_[##YW
M$, D/0YHON.D6\HQJ24UEA=_S-9L[D_8;TN7^A=NBP98J/"28;BMM/[$\CR+
MH58F3]V2N7I=SY\2C>F' %9@'%E31OAE6URNVJ.I5O:O:N_9SZ4X9&"@L;JN
M:4_8ZK]JN(Z[9H9$SH9IW[HWY_X>:\R[\NLMDF_@      56UN\!+#4PXRH(
MVI'(K8*U$S5RNR[5Z\V629%:0 #O6.U5=[NU+;;=$LM74R)'&SI5387HWPK!
M@W"-#9Z=&;43<Y7M^?(OPG&3 QG'6.+%@FVK67^L;$FY&Q,[:1^:Y;F\?&5K
MQGK-WFMEGBPM0QT%*YBM;+4(CY47Z2<Q'_\ QMTB?K-/]S'_ /4].PZP&/;9
M4NEJKE%<V.3+DJF)J(B]**U$4GC1GK"V'$U3!;KW$^TW%S41))%3D9'Y;\G9
M]KXR;8WMD8U\;D<QR9HYJYHJ=)^@5'UM<!R4%\9BVAA>ZDK-F*J5J;HWHF2+
MDG2B<>DKP  >IAFQUN([Y26JV1.DJ:EZ,1$3/93/>J]2&Q+!UAI\,X:H+129
MK%2Q(Q%7BJ\Z^4]D          \G%S9WX5O+:-7-J5HYDB5O%';"Y9>,UZ+B
MO$L"K%+>KBV1BJUR+,[-%3B?/;?B/Z\N'WRDDZO.D"[T>DRWTEQKYJJEN/\
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M?H%9^*</<Z:/OT"L_%.,FP%HKPO@6Y5%?AVFGBJ9XN1>LDRO39SSX+UH9R
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MH^_0*S\4X>YTT??H%9^*<97@#1GAO =153X=IIH9*EJ-D6257YHG#B9H
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M.U%X+WB1$3),DX
M                     &)Z3<#6['V&I+5<]ICD7E()F+DZ*3)<EZTZ4YRA
MF.L(W7!5_FM-[AV)F]LR1OP)6\SFKXC'P!U<57<B)SEG]7+0HYKZ?%.,*9JI
MLH^AHI$5%:N>Z1Z=/0GC+0
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M,C
M         ,%TX7^IPSHPOMSH'-;5,B1D:NZ7.1N[KR537X][I'ND>Y7/>JN<
MY>*JO.?D$IZMV*:K#VDNW4L&T^FNCTI9H]O)N_@[+G5/[E[      "+-9+%,
MF&=&5=V*^6.KKG-I8I8G;*L55S5<^\BIXRB:JJJJN555=ZJO. 3)JMXJ=8M(
M<5OEG>RDNB)"K$X.D^9YU+M@
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M:1S4T2OCI:IDLRI\UN],_*J%+P"0] %GJ+QI5L*4RM3L6=M5)G]%BYJ7\
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M*V.%CGR.7)&M3-54N#JT:)ZG"L#\0X@C6*Z54:-AIURSAC7>NU^TN[=S$]@
M^.5&M57*B(G%5,!Q=I>P;A9\T-PNS):N)VP^GIF\I(B][A_4P^HUEL%,V>19
M<I,U[;.#9R_J=ZWZQ6 ZRLBIW5-;3I(N7*S4^3&]]4524+#?+9?Z%E99JZ"L
MI7\)(G9HIZ( //Q#:*6_62LM=PC;)2U4:QO:Y,T__L\E*"Z3='=ZP)>IX*^F
M>M Z1W8U4U,V2-YM_,N7,84=FWT-5<:R*EH8)*BIE<C61QIFKEZ$+F:N&BU^
M#;3)=;W3[%[K$3M'*BK"SHZE7/?WB:@
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M     ''52<C332HF>PQ79=Y%-<..KU)B'%]WNTS$C?55#GJQ%S1O-E_0\(
M%O\ 4UN=158'NU#-(CH:*L1(6Y;VHYJ*O]2P     !@>F_%DN#='5SNE*F=6
MJ-@A[;)4<]<MKQ<2@%1-+4SRSU#W232N5[WN7-7.5<U4XP6.U2<>U,%XFPI<
MJQ%HIF;=$R3-5;(G%K5Z,M^1;$
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M*=,^*J(F:\"UNJ5H]K+='58JO%/R25<38Z)CT[;8SS5^7-GS=19,
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MK8B+L39)$CTYT:G'QDV,8V-C6,:C6M3)$1,D1#Z
M                                          1CI<TQ671ZC*9S%N-V
MD152DA>B+&G,KUYDZN) 5;K,XOG7WBAMM.B.S[5'.54Z-YD.$=:&L2X-CQ39
MX.Q'JB<K2/7:CZU1>*%EL-7^VXEL]/<[+5QU5'.U'->Q<\NI4YE3H/4 !!.F
M'0#;L3/J+MAA8[==E3:= C<HIEYUR3@Y?(59Q-@?$N&:B:.\V:L@;%O=,D:N
MCRZ=I-QCGE.>AHZJX5#:>@I9ZJH=O2*&-7N7IW(2_HST 8CQ3)'4WQK[):U1
MK]J5GOLB*N]$;S+WRWN#,+6O"%AI[39*=L--"F]43MI'<[G+SJI[@ (TTLZ8
M+)H];'!*U;A=)-Z4D+T1S$Z7+S$$2ZT.*%E>L5HM;8U7M45SU5$,CP1K/NEK
MF4^+K3'##)(B=E4KUV8F\ZN:N]?$64M-RH[O;X:ZVU,532S-1S)(W;2*BG;
M
M      ,8TF8F;A# UWO;HY)%I8LVHS+/:5=E%W]:H:\;K<*J[7.JN%QG?45E
M3(LDLKUS5RJIU03;JKXW?A[&:6.ID>M!=W-C:SBC9OFKU9YKGXBZ0 !Q55/#
M5P/@JHHYH7IDYDC4<UR=:*>5[4\/?4=L_#,]1V*"PVBWU"3T-LHJ:9$5$DBA
M:UV2]:(>D  8MI0Q*N$<"7>\LV5FIXO>FJJ)F]51$RSX\<_$:];O<JN\72JN
M-RG?45E5(LDLC^+E53I@L%JG8\J;=B%V%ZVH1;=6=M3M>O\ ARIS-[_]BWH
M
M     !$>M-#52:(+HZF>C8HWQNG;])FTF[RY%'$X &9:&<DTK84^WQFPT
M   @S6^@GET;4[H8Y'QQUC'2*U-S4W[UZLRF8!F6AICGZ4\+(U%54N$2[NC:
M0V&@
M          'BXSP]2XIPQ<;+7M1T%7$K-_,O%%\2HBFO;&>%[GA"_P!3:;U3
M/AFB<J,>K<FRLSW.:O.BGA@L;JG:/)JR[28KNU*]E)3(B4/*LW2O7B]N?1EQ
MZRV0     !X&/L.,Q;@^ZV*298&UL6PDB)GLJBHJ+Y40UZ8HL-=AJ^UEIND+
MXJBFD<SMFJB/1%W.3I13R@65U2< U$EPFQ;<8WQ01MY.D:^/=*J\7HJ]&[)4
MZ2U0
M           ,5Q]@##^.J*.GQ#1),Z'/D96N5KXU7H5/,0L_56MVTNQB.K1,
M]R+"T]W"&K7AFT7!*J\5-1=VMR5D,J;#$7I5$X]XG&CIH:.EBIJ2)D-/$U&1
MQL3)&M3@B(<H      ,/T@Z.,.X[I.3OE$UU0Q%Y*IC79D8N6[>G%.I2#;IJ
MKN1T7L5B'::KO?.R(LLDZLC+,&ZMF'++=&5EWJY[NV/)6P2MV&;72J)Q[Q.-
M)30T=+%34D3(8(FHQD;$R:U$X(B'*
M                                         >1B?$EHPO;EK[_7PT5*
MBY;<B\5Z$1-Z^(B*Z:S&$:2OF@IJ>OK(8UR;/''DU_6F>\RG VFO!V+9(*:"
MX=AW&97(VEJFJQRY;^/#^I):+FF:;T
M                                              !Y6*[Y38;P[<+Q
M7(JT]'$LKFHJ(KLN9,^<H'I+QY=<>7^>ON4TB4NVJTU)MJK(&\R(G3EQ4Q$^
MM56N1S55KDX*BY*A;+56TFSW>";"^(*QTU93M1U%+,[-TC.=F?%53CWBQ@
M
M             !#FMB]S-$-7L.5NU50(N2\4V^!2, SK077/M^EC#D\<3IE6
MHY-6MXY.W*IL%
M                             ,!TYX6DQ=HVNMOIDD=5,:E1 R/B][%S
M1OC* S1203213,<R6-RM>UR9*U4XHI^ 3;JIX2K;OCYE]:U66^U(JND5-SWN
M3)&IU\Y=(
M                         $'::=!-)C"I?=\.R0V^[*BK+'L=I4NYE54X
M+UE<KSH<QS:Z^2E]K]95[.7OM,Q7L=WE,OP+JZ8EO,]--?U;::!^:R(Y-J9$
MZ-GFS[Y;#!&$K5@VQ16NR4Z10LWO=EVTCOI.7G4]\
M
M
(       __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
